Document:

EX-10.2

 Exhibit 10.2 

EVALUATION, OPTION AND LICENSE AGREEMENT 

This Evaluation, Option and License Agreement (the “Agreement”) is effective as of April 28, 2017 [/s/ YH] (the
“Effective Date”) by and among IDEAYA BIOSCIENCES, INC., a Delaware corporation located at 280 Utah Avenue, Suite 250, South San Francisco CA 94080, U.S.
(“Ideaya”), and CANCER RESEARCH TECHNOLOGY LTD., a company registered in England & Wales under number 1626049 and located at the Angel Building, 407 St John
Street, London EC1V 4AD, England (“CRT”), and UNIVERSITY OF MANCHESTER, a public research university located at Oxford Road, Manchester M13 9PL, England
(“Manchester”) (with CRT and Manchester, collectively, “Institute”). Ideaya, CRT, Manchester and Institute are referred to individually as a “Party” and collectively as the
“Parties”. 
 RECITALS 

A. [***] 
 B. Ideaya is a biotechnology company
with expertise in medicinal chemistry. 
 C. Ideaya and Institute desire to enter into an agreement under which CRT grants to Ideaya evaluation
rights and options to certain technology and intellectual property rights controlled by CRT arising out of or relating to Manchester PARG program. 

D. In addition to its said evaluation work, Ideaya shall further develop the PARG program by applying is medicinal chemistry expertise to develop the
small molecule compounds that the program has generated. 
 E. If Ideaya fails or chooses not to exercise its option rights in respect of the
technology and intellectual property then CRT shall have the exclusive rights to develop and commercialize the same. 
 NOW,
THEREFORE, in consideration of the foregoing and the covenants and promises contained in this Agreement and intending to be legally bound, the Parties agree as follows: 

 

	1.	 DEFINITIONS 

Capitalized terms used in this Agreement (other than the headings of the Sections or Articles) have the following meanings set forth in this
Article 1, or, if not listed in this Article 1, the meanings as designated in the text of this Agreement. 
 1.1
“Affiliate” means, with respect to a Party, any Person that now or hereinafter controls, is controlled by or is under common control with such Party. For the purposes of the definition in this Section 1.1,
the word “control” (including, with correlative meaning, the terms “controlled by” or “under the common control with”) means the actual power, either directly or indirectly through one (1) or
more intermediaries, to direct or cause the direction of the management and policies of such Person, whether by the ownership of at least fifty percent (50%) of the voting stock of such Person, by contract or otherwise. 

1.2 “Applicable Law” means all applicable laws, rules, and regulations operational for a Party’s conduct of the
activities agreed in this Agreement, including: (a) any rules, regulations, guidelines or other requirements of Regulatory Authorities; and (b) the OECD Convention Against Bribery of Foreign Public Officials in International Business
Transactions, legislation implementing such Convention or the U.S. Foreign Corrupt Practices Act, and any other international anti-bribery convention or any other local anti-corruption and bribery law, in each case that may be in effect from time to
time in any relevant legal jurisdiction in the Territory. 

  
 [***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. 
 Confidential treatment has been
requested with respect to the omitted portions. 

 1.3 “Business Day” means any day other than a Saturday, Sunday or
other day that is a recognized national holiday in the U.S. or England or that is a day that commercial banks are authorized to close under the Applicable Laws of, or are in fact closed in, San Francisco, CA or London, England. 

1.4 “Calendar Quarter” means the respective periods of three (3) consecutive calendar months ending on
March 31, June 30, September 30 and December 31. 
 1.5 “Calendar Year” means: (a) for the first
Calendar Year of the Term, the period beginning on the Effective Date and ending on December 31, 2017; (b) for each Calendar Year of the Term thereafter, each successive period beginning on January 1 and ending twelve (12) consecutive
calendar months later on December 31; and (c) for the last Calendar Year of the Term, the period beginning on January 1 of the Calendar Year in which the Agreement expires or terminates and ending on the effective date of expiration or
termination of this Agreement. 
 1.6 “Commercialize” means to promote, market, import, export, distribute, sell
(and offer for sale or contract to sell) or provide product support for a Licensed Product. 
 1.7 “Compendia
Listing” means a listing of a Licensed Product for use in an Indication in the United States that is supported by a citation in at least one of the following authoritative drug reference books (or in another similar authoritative drug
reference book), in each case that is relied on by Third Party payors in authorizing reimbursement for such Licensed Product for such Indication: (a) the American Society of Health-System Pharmacists’ American Hospital Formulary Service;
(b) the U.S. Pharmacopoeia Drug Information; or (c) the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. 

1.8 “Confidential Information” has the meaning set forth in Section 9.1. 

1.9 “Control” means, with respect to any physical material,
Know-How or intellectual property right (including Patents), that a Party owns or has a license to, the ability to grant to another Party access, a license or a sublicense (as applicable) to such physical
material, Know-How or intellectual property right for the purpose provided for herein without violating the terms of any agreement or other arrangements with any Third Party existing at the time such Party
would be first required hereunder to grant the other Party such access, license or sublicense. 
 1.10 “CRT Background
IP” means any Patents and Know-How that: (a) are Controlled by CRT or its Affiliates as of the Effective Date or during the performance of the Research Plan; and (b) were or have been
discovered at the CRUK Drug Discovery Unit at Manchester; and (c) relate specifically to PARG and are necessary or reasonably useful for Ideaya to perform its obligations under the Research Plan. For clarity, CRT Background IP includes the
Patents and Know-How identified on Exhibit A. 

  
 2 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. 

Confidential treatment has been requested with respect to the omitted portions. 

 1.11 “Development” means, with respect to a Licensed Product, those
activities, including clinical trials and related regulatory activities, that are necessary or useful to: (a) obtain the approval by the applicable Regulatory Authorities of the Regulatory Approval Application with respect to such Licensed
Product in the applicable regulatory jurisdiction, whether alone or for use together, or in combination, with another active agent or therapeutic product; (b) maintain such approvals; or (c) obtain or maintain Compendia Listings with
respect to such Licensed Product. To avoid confusion, Development does not include the conduct of Research or Phase IV Clinical Trials. 

1.12 “Disputed Matter” has the meaning set forth in Section 13.1(a). 

1.13 “EMA” means the European Medicines Agency, and any successor thereto. 

1.14 “Executive Officers” means: (a) in the case of Institute, the Director of Business Development and the
Director of the CRUK Manchester Institute, or that officer’s designee; and (b) in the case of Ideaya, the Chief Executive Officer, or that officer’s designee. 

1.15 “FDA” means the U.S. Food and Drug Administration, and any successor thereto. 

1.16 “Field” means all therapeutic uses in any species. 

1.17 “First Commercial Sale” means, for each Licensed Product in each country, the first arm’s-length sale to a Third Party for use in such country after Regulatory Approval of such Licensed Product in such country. A First Commercial Sale will not include any Licensed Product supplied for use in
clinical trials, for research or for other non-commercial uses, or as part of a compassionate use program (or other program for providing Licensed Product before it has received Regulatory Approval in a
country). 
 1.18 “Force Majeure” has the meaning set forth in Section 13.6. 

1.19 “GAAP” means U.S. generally accepted accounting principles, consistently applied. 

1.20 “GLP” means the principles and guidelines for good laboratory practice as set out in: (a) the
UK Statutory Instrument 1999 No. 3106, The Good Laboratory Practice Regulations 1999, as amended; (b) Title 21 of the United States Code of Federal Regulations part 58 as may be supplemented or amended from time to time; (c) in all
guidance published by the European Commission and/or US Food and Drug Administration pursuant to such legislation from time to time; and (d) other legislation relating to good laboratory practice applicable in the countries where the Research
Plan is being conducted. 
 1.21 “[***]” has the meaning set forth in Section 13.1(b).

 1.22 “Ideaya Indemnitee” has the meaning set forth in Section 12.2. 

1.23 “Ideaya Project IP” means any Patents and Know-How that: (a) are
Controlled by Ideaya or its Affiliates during the Term; and (b) cover or claim Inventions that are conceived or made in the performance of the Research Plan during the Research Term (and that are not Joint Inventions). 

1.24 “IND” means an investigational new drug application submitted to the FDA in conformance with Applicable Law, or
the international equivalent of any such application in another country. 
 1.25 “Indication” means a broad disease
classification block, such as, by way of example, oncologic diseases, immunological diseases or metabolic diseases. 

  
 3 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. 

Confidential treatment has been requested with respect to the omitted portions. 

 1.26 “Indemnitee” has the meaning set forth in
Section 12.3. 
 1.27 “Insolvent Party” has the meaning set forth in
Section 10.2(b). 
 1.28 “Institute Indemnitee” has the meaning set forth in
Section 12.1. 
 1.29 “Invention” means any and all inventions that are conceived or made
by, or on behalf of, a Party or its Affiliates in the performance of its obligations, or the exercise of its rights, under this Agreement. 

1.30 “Joint Invention” means any Invention conceived or made jointly by or on behalf of the employee(s), contractor(s)
or agent(s) of two (2) or more Parties (or their Affiliates). 
 1.31 “Joint Invention Patents” has the meaning
set forth in Section 8.1(b). 
 1.32 “JRC” has the meaning set forth in
Section 4.1(a). 
 1.33 “Know-How” means
scientific and technical information, materials, results and data, in any tangible or intangible form, including, preclinical data, clinical trial data, databases, practices, methods, techniques, specifications, formulations, formulae, knowledge, know-how, skill, experience, test data including pharmacological, biological, chemical, biochemical, toxicological and clinical materials, test data, analytical and quality control data, stability data, studies and
procedures. For clarity, Know-How does not include any Patents. 
 1.34
“Liaison” has the meaning set forth in Section 4.2(a). 
 1.35 “Licensed
Product” means any pharmaceutical preparation that: (a) incorporates a PARG Inhibitor [***]), either alone or in combination with another active ingredient(s); and (b) is covered or claimed by a Valid Claim of a Patent that
is part of the Product IP (whether during or after the Research Term) or in the case that the Patent has expired or is no longer valid, the [***] anniversary of the First Commercial Sale of the Licensed Product. 

1.36 “Losses” has the meaning set forth in Section 12.1. 

1.37 “Manufacturing” means all activities related to the production, manufacture, processing, filling, finishing,
packaging, labeling, inspection, receiving, holding and shipping of Licensed Products, or any raw materials or packaging materials with respect thereto, or any intermediate of any of the foregoing, including process and cost optimization, process
qualification and validation, clinical manufacture, commercial manufacture, stability and release testing, quality assurance and quality control. 

1.38 “NDA” means a new drug application submitted to the FDA in conformance with Applicable Law, or the international
equivalent of such application in another country. 
 1.39 “Net Sales” means the gross amount received by Ideaya (or
its Affiliate, licensee or Sublicensee) for sales of a Licensed Product to a Third Party purchaser, less the following to the extent included in such invoice or otherwise actually allowed or incurred with respect to such sales: (a) discounts,
including cash, trade and quantity discounts, price reduction programs, retroactive price adjustments with respect to sales of a Licensed Product, charge-back payments and rebates granted to managed health care organizations or to federal, state and
local governments (or their respective 

  
 4 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. 

Confidential treatment has been requested with respect to the omitted portions. 

 
agencies, purchasers and reimbursers) or to trade customers, including but not limited to, wholesalers and chain and pharmacy buying groups; (b) credits or allowances for rejections or
returns of Licensed Products, including for recalls or damaged goods; (c) freight, postage, shipping and insurance charges for delivery of Licensed Products, to the extent billed; (d) customs duties, surcharges and other governmental
charges incurred in connection with the exportation or importation of a Licensed Product; (e) costs due to the factoring of receivables; and (f) taxes, duties or other governmental charges levied on, absorbed or otherwise imposed on sale
of Licensed Products, including value-added taxes, or other governmental charges otherwise measured by the billing amount, when included in billing, as adjusted for rebates and refunds, but specifically excluding taxes based on net income of the
seller; in each case, only if the foregoing deductions are calculated in accordance with GAAP. 
 If Ideaya, after reasonable efforts, cannot calculate
accurately the Net Sales of a licensee or Sublicensee in a particular country, the Parties will meet and negotiate in good faith an appropriate means for calculating Net Sales in such a situation. 

For sake of clarity and avoidance of doubt, sales on an arm’s length basis by Ideaya (or its Affiliate, licensee or Sublicensee) of a Licensed Product to
a Third Party distributor of such Licensed Product in a given country will be considered a sale to a Third Party purchaser. Any Licensed Products that are: used (but not sold for consideration) for promotional or advertising purposes (including free
samples); used for clinical or other research purposes; or supplied as part of a compassionate use program (or other program for providing Licensed Product before it has received Regulatory Approval in a country), will in each case not be considered
in determining Net Sales hereunder. 
 If a Licensed Product is sold as a combined product or service, Net Sales, for purposes of determining royalty
payments on such Licensed Product, will be calculated by multiplying the Net Sales of the combined product or service by the fraction A/A+B, in which A is the gross selling price (in the applicable country) of the Licensed Product portion of
combined product or service when such Licensed Product is sold separately during the applicable accounting period in which the sales of the combined product were made, and B is the gross selling price (in the applicable country) of the other
products or services, as the case may be, of the combined product and/or service sold separately during the accounting period in question. All gross selling prices of the components of the combined product or service will be calculated as the
average gross selling price of the components during the applicable accounting period for which the Net Sales are being calculated. 
 In any country, if no
separate sale of either such above-designated Licensed Product or such above designated elements of the end-user product and/or service are made during the accounting period in which the sale was made, or if
gross retail selling price for an active functional element, component or service, as the case may be, cannot be determined for an accounting period, Net Sales allocable to the Licensed Product in each such country will be determined by mutual
agreement reached in good faith by the Parties prior to the end of the accounting period in question based on an equitable method of determining same that takes into account, on a
country-by-country basis, variations in potency, the relative contribution of each active agent, component or service, as the case may be, in the combination, and
relative value to the end user of each active agent, component or service, as the case may be. 
 1.40 “Option” has
the meaning set forth in Section 2.1. 
 1.41 “Option Exercise Date” has the meaning
described in Section 2.2. 

  
 5 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. 

Confidential treatment has been requested with respect to the omitted portions. 

 1.42 “Option Period” has the meaning described in
Section 2.1. 
 1.43 “PARG” means: [***] poly
ADP-ribose glycohydrase [***]; and [***]. 
 1.44 “PARG Inhibitor” means any
small molecule that: (a) binds and inhibits PARG; and (b) is covered or claimed by, or developed using any part of, the Product IP. 

1.45 “Patent” means any patent application or granted patent or similar or equivalent form of protection
anywhere in the world, including utility model and design patents and certificates of invention and all provisionals, non-provisionals, divisionals, continuations, continuations-in-part, reissues, renewals, extensions, additions, and/or supplementary protection certificates. 

1.46 “Person” means any corporation, limited or general partnership, limited liability company, joint venture, trust,
unincorporated association, governmental body, authority, bureau or agency, any other entity or body, or an individual. 
 1.47
“Phase I Clinical Trial” means any clinical study conducted on sufficient numbers of human subjects to establish that a therapeutic product is reasonably safe for continued testing and to support its continued testing in Phase II
Clinical Trials. A “Phase I Clinical Trial” will include any clinical trial that would satisfy requirements of 21 C.F.R. § 312.21(a) and Medicines for Human Use (Clinical Trials) Regulations 2004. 

1.48 “Phase II Clinical Trial” means any clinical study conducted on sufficient numbers of human subjects that have
the targeted disease of interest to investigate the safety and efficacy of a therapeutic product for its intended use and to define warnings, precautions, and adverse reactions that may be associated with such therapeutic product in the dosage range
to be prescribed. A “Phase II Clinical Trial” will include any clinical trial that would satisfy requirements of 21 C.F.R. § 312.21(b) and Medicines for Human Use (Clinical Trials) Regulations 2004. 

1.49 “Phase III Clinical Trial” means any clinical study intended as a pivotal study for purposes of seeking
Regulatory Approval that is conducted on sufficient numbers of human subjects to establish that a therapeutic product is safe and efficacious for its intended use, to define warnings, precautions, and adverse reactions that are associated with such
therapeutic product in the dosage range to be prescribed, and to support Regulatory Approval of such therapeutic product or label expansion of such therapeutic product. A “Phase III Clinical Trial” will include any clinical trial that
would or does satisfy requirements of 21 C.F.R. § 312.21(c), and Medicines for Human Use (Clinical Trials) Regulations 2004, whether or not it is designated a Phase III Clinical Trial. 

1.50 “Phase IV Clinical Trial” means clinical study of a therapeutic product on human subjects commenced after receipt
of Regulatory Approval of such therapeutic product for the purpose of satisfying a condition imposed by a Regulatory Authority to obtain Regulatory Approval, or to support the marketing of such therapeutic product, and not for the purpose of
obtaining initial Regulatory Approval of a therapeutic product. 
 1.51 “Post-Project Ideaya Patents”
means: solely if Ideaya exercises the Option, any Sole Invention Patents that: (i) are not within the Ideaya Project IP but which are derived from or incorporate CRT Background IP and/or Ideaya Project IP and/or Joint Inventions; and
(ii) cover or claim Inventions that cover the composition of matter of, manufacturing processes (including intermediates) or formulations of, or methods of using Licensed Products. Post-Project Ideaya

  
 6 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. 

Confidential treatment has been requested with respect to the omitted portions. 

 
Patents do not include any Patents that: (x) are owned or controlled by a Third Party who becomes a
successor-in-interest to Ideaya (whether by merger, acquisition, share purchase, asset purchase or other transaction); and (y) either: (I) exist as of the date that
such Third Party became Ideaya’s successor-in-interest; or (II) exist after the effective date that such Third Party became Ideaya’s successor-in-interest and were conceived or made outside the course of conducting Ideaya’s activities under this Agreement during the Research Term. 

1.52 “Pounds” or “£” means the legal tender of England. 

1.53 “Product IP” means together CRT Background IP, Ideaya Project IP, Joint Invention Patents and Post-Project Ideaya
Patents. 
 1.54 “Prior CDA” has the meaning set forth in Section 9.4. 

1.55 “Reasonable Efforts” in relation to Party and activity means the efforts that a company in the same
industry sector, of comparable value, business model and resources as the Party would expend in pursuing that activity (as of the time such efforts would be expended) having regard to the market potential, profit potential and anticipated benefits
and duration of the benefits, strategic value and stage of development, and taking into account all other relevant factors (based on all facts and circumstances existing as of the time such efforts or resources would be used). 

1.56 “Regulatory Approval” means any and all approvals (including Regulatory Approval Applications,
supplements, amendments, pre- and post-approvals, pricing and reimbursement approvals, where applicable), licenses, registrations or authorizations of any Regulatory Authority that are necessary for the
manufacture, distribution, use or sale of a Licensed Product in a regulatory jurisdiction. 
 1.57 “Regulatory Approval
Application” means: (a) in the United States, an NDA (or a supplemental NDA for following Indications); and (b) in another country or regulatory jurisdiction, an equivalent application for regulatory approval required before
commercial sale or use of a Licensed Product (or with respect to a subsequent Indication) in such country or regulatory jurisdiction. 

1.58 “Regulatory Authority” means the applicable national (e.g., the FDA and MHRA), supra-national
(e.g., the EMA), regional, state or local regulatory agency, department, bureau, commission, council or other governmental entity that, in each case, governs the approval of pharmaceutical and healthcare products in such applicable regulatory
jurisdiction. 
 1.59 “Regulatory Data” has the meaning set forth in
Section 7.1. 
 1.60 “Research” means any
non-clinical research conducted on PARG Inhibitors, including the following activities: (a) identifying and evaluating molecules as potential Licensed Products; (b) conducting a lead optimization
program to optimize such potential Licensed Products (including the conduct of [***]); and (c) conducting preclinical development on such Licensed Products to prepare them for IND submission (including the conduct of toxicological studies, and
related bioanalytical and pharmacokinetic activities). To avoid confusion, Research excludes the conduct of Development. 
 1.61
“Research Field” means the Research of PARG Inhibitors. 

  
 7 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. 

Confidential treatment has been requested with respect to the omitted portions. 

 1.62 “Research Plan” means the document attached as
Exhibit B. 
 1.63 “Research Term” means the period beginning on the Effective Date and ending
on the second (2nd) anniversary thereof, unless extended by the mutual written agreement of the Parties. 

1.64 “Royalty Term” has the meaning set forth in Section 3.5. 

1.65 “Rules” has the meaning set forth in Section 13.1(b). 

1.66 “Sole Invention” means any Invention conceived or made solely by or on behalf of a Party (or its
Affiliate) and its employees, contractors and/or agents. 
 1.67 “Sole Invention Patents” has the
meaning set forth in Section 8.1(b). 
 1.68 “Sublicensee” includes each sublicensee at
whichever tier of sublicensing unless expressly stated otherwise. 
 1.69 “Sublicense Revenue” means
any cash consideration (including milestone payments, but only to the extent such milestone payments exceed the milestone payments set forth in Section 3.2(a)), and the cash equivalent of all other consideration (including
stocks, shares and any other form of non-cash consideration), due to a Party for a sublicense (if such Party is Ideaya) or a license (if such Party is CRT) of Product IP to a Third Party, excluding:
(a) amounts paid for equity of Ideaya or CRT (as applicable), up to its fair market value; (b) debt financing of Ideaya or CRT (as applicable) by such Third Party; (c) payments or reimbursements for Research, Development or
Commercialization services that are undertaken by Ideaya or Institute (as applicable) for products or services; (d) payments or reimbursements to Ideaya or CRT (as applicable) for Patent expenses related to products or services;
(e) payments for the supply of products or materials used in performance of services; (f) amounts received by Ideaya or CRT (as applicable) from a Third Party in consideration for intellectual property rights that are not Product IP;
(g) payments received on sales of products (including without limitation Licensed Products) or services (whether royalties, profit-share payments or otherwise); or (h) payments on the sale of Ideaya or CRT (as applicable). 

1.70 “Subsequent Termination Notice” has the meaning set forth in
Section 10.2(a). 
 1.71 “Term” has the meaning set forth in
Section 10.1. 
 1.72 “Territory” means the world. 

1.73 “Third Party” means any Person other than: (a) Institute; (b) Ideaya; or (c) an Affiliate
of either Party. 
 1.74 “Tobacco Party” means any Person with a business of making, distributing or
selling tobacco products or who makes the majority of its profits from the importation, marketing, sale or disposal of tobacco products or an Affiliate of such Person. 

1.75 “Transferred Technology” means: (a) copies of all tangible recordings or embodiments of
Know-How that is part of CRT Background IP and Controlled by CRT, including (to the extent that they form part of the CRT Background IP) without limitation all materials, preclinical or clinical data,
databases, designs, assays, protocols, synthetic methodologies, analytical systems, reports, internal notes or memorandum and documentation relating to the Research, 

  
 8 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. 

Confidential treatment has been requested with respect to the omitted portions. 

 
Manufacturing or Development of the Licensed Products that is Controlled by CRT; and (b) copies of all Patent files associated with the CRT Background IP, including without limitation the
complete texts of all patents and patent applications and copies of all office actions, office action responses and other official communications received from, or filed with, all relevant patent offices by CRT. 

1.76 “United States” or “U.S.” means the United States of America, and
its territories, districts and possessions. 
 1.77 “Valid Claim” means a claim in a Patent
application or an issued Patent that is part of the Product IP and that has not: (a) expired or been canceled; (b) been declared invalid by an unreversed and unappealable or unappealed decision of a court or other appropriate body of
competent jurisdiction; (c) been admitted to be invalid or unenforceable through reissue, disclaimer or otherwise; or (d) been abandoned in accordance with or as permitted by the terms of this Agreement or by mutual written agreement of
the Parties. 
  

	2.	 OPTION AND LICENSES 

2.1 Option Grant and Option Period. CRT hereby grants to Ideaya during the Option Period a first and exclusive option to obtain
the licenses described in Section 2.4(b) (the “Option”). The “Option Period” will: (a) start on the Effective Date; and (b) end on the first to occur of the following:
(i) the end of the Research Term; or (ii) the completion of the IND-enabling GLP-toxicology studies on a PARG Inhibitor. 

2.2 Option Exercise. During the Option Period, Ideaya may exercise the Option by: (a) so notifying CRT in writing; and
(b) paying the license fee described in Section 3.1(b). The date that Ideaya exercises the Option shall the “Option Exercise Date”. 

2.3 Exclusivity. Subject to Institute’s retained rights under Section 2.6: (a) no Party shall
undertake a drug discovery program in the Research Field during the Research Term (except for the conduct of the Research Plan under this Agreement); and (b) no Party shall grant any Third Party any rights or licenses under its Background IP or
Ideaya Project IP as the case may be during the Option Period. 
 2.4 Licenses to Ideaya. 

(a) Research License. 

(i) Subject to the terms and conditions of this Agreement (including Section 2.6), CRT hereby grants to
Ideaya a non-exclusive, sublicensable, non-transferable, royalty-free license under CRT Background IP and CRT’s interest in any Joint Invention Patents to conduct
Ideaya’s responsibilities under the Research Plan during the Research Term. 
 (ii) Subject to the terms and conditions of this
Agreement (including Section 2.6), Ideaya hereby grants to Manchester a non-exclusive, sublicensable, non-transferable, royalty-free license under Ideaya Project IP
and Ideaya’s interest in any Joint Invention Patents to conduct Manchester’s responsibilities under the Research Plan during the Research Term. 

  
 9 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. 

Confidential treatment has been requested with respect to the omitted portions. 

 (b) License After Option Exercise. If Ideaya exercises its Option, then,
subject to the terms and conditions of this Agreement (including Section 2.6): 
 (i) CRT hereby grants to
Ideaya an exclusive, sublicensable, transferable, royalty-bearing license under the CRT Background IP and CRT’s interest in any Joint Invention Patents to Research, Develop, Manufacture, use, sell, offer for sale, have sold, distribute, import,
export and otherwise Commercialize Licensed Products in the Field in the Territory. 
 (ii) CRT hereby grants to Ideaya a non-exclusive, sublicensable, transferable, royalty-free license under the DDU FTO Patents (defined below) to Research, Develop, Manufacture, use, sell, offer for sale, have sold, distribute, import, export and
otherwise Commercialize Licensed Products in the Field in the Territory in either case to Research, Develop, Manufacture, use, sell, offer for sale, have sold, distribute, import, export and otherwise Commercialize Licensed Products in the Field in
the Territory. The “DDU FTO Patents” mean any Patents that: (A) are not Patents within the CRT Background IP; (B) cover the composition of matter of, manufacturing processes (including intermediates) or formulations of, or
methods of using Licensed Products; (C) are Controlled by CRT or its Affiliates as of the Effective Date or during the Term; and (D) claim inventions that are conceived or made by or on behalf of individuals that are employed or affiliated
with the CRUK Drug Discovery Unit at Manchester. For sake of clarity and avoidance of doubt, in order for a Patent to be a DDU FTO Patent all of (A)-(D) (inclusive) must be satisfied. 

2.5 No Additional Licenses. Except as expressly provided in this Agreement, nothing in this Agreement grants either Party any
right, title or interest in and to the intellectual property rights of the other Party, including any other Patents or Know-How (expressly, by implication or by estoppel). If Ideaya fails to validly exercise
the Option within the Option Period for any reason including termination or expiry of this Agreement, then, pursuant to Article 10, Ideaya shall have no further rights in respect of CRT Background IP, and CRT shall be free to deal with and dispose
of the CRT Background IP in such manner as it may in its discretion decide, subject to the surviving terms and conditions of this Agreement. 

2.6 Sublicensing and Retained Rights. 

(a) Sublicensing. The licenses granted to Ideaya in Section 2.4 will be freely sublicensable by Ideaya
through multiple tiers. Ideaya shall remain responsible for each permitted Sublicensee’s compliance with the applicable terms and conditions of this Agreement and shall comply with the following conditions for sublicensing: 

(i) the Sublicensee has the same obligations to the Licensee as are commensurate with those which Ideaya has to CRT under this
Agreement, except where it is not legally possible to include such obligations in the sublicense; and 
 (ii) promptly following the
grant of each sublicense, Ideaya shall provide a [***] copy of the sublicense to CRT. 
 (b) Retained Rights. CRT retains the
right to use the exclusively licensed CRT Background IP and is hereby granted the non-exclusive right under the Project IP and the Joint Invention Patents to use in either case solely for academic, non-commercial research and teaching purposes. CRT may sublicense such retained right to any academic and not-for-profit institutions,
subject to establishing, in any agreement with such academic and not-for-profit institution, a restriction to pursue only academic,
non-commercial research and teaching and to establishing confidentiality, non-use and intellectual property protections at least as protective of Ideaya as those in this
Agreement. 

  
 10 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. 

Confidential treatment has been requested with respect to the omitted portions. 

	3.	 COMPENSATION 

3.1 Option Fee and License Fee. 

(a) Option Fee. In consideration of the exclusive option granted to Ideaya, Ideaya shall pay CRT an option fee of One Hundred
Thousand Pounds (£100,000) within [***] days after the Effective Date. 
 (b) License Fees. If Ideaya exercises the
Option, then Ideaya shall pay CRT a license fee of Four Hundred Thousand Pounds (£400,000) within [***] days of notifying CRT in writing of such exercise. If Ideaya does not exercise the Option, then Ideaya will not owe Institute any payments
under this Section 3.1(b). 
 (c) No Research Support. Ideaya will not be obligated to pay
Manchester or CRT any support for the research conducted by Institute under this Agreement. 
 3.2 Milestone Payments and Sublicense
Revenue. 
 (a) Development and Commercial Milestones. If Ideaya exercises the Option, then, subject to
Section 3.2(b) and Section 3.2(c), Ideaya shall make the following milestone payments set forth below to CRT after the achievement of each indicated event by Ideaya (or any of its Affiliates,
licensees or Sublicensees). If Ideaya does not exercise the Option, then Ideaya will not owe Institute any payments under this Section 3.2(a). 
  

			
	 Event
	  	Milestone
Payment
	 (i) [***]
	  	£[***]
	 (ii) [***]
	  	£[***]
	 (iii) [***]
	  	£[***]
	 (iv) [***]
	  	£[***]
	 (v) [***]
	  	£[***]
	 (vi) [***]
	  	£[***]
	 (vii) [***]
	  	£[***]
	 (viii) [***]
	  	£[***]
	 (ix) [***]
	  	£[***]
	 (x) [***]
	  	£[***]

  
 11 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. 

Confidential treatment has been requested with respect to the omitted portions. 

 (b) Milestone Payment Conditions. Each milestone payment set forth in
Section 3.2(a) shall be paid up to [***] times per Indication, whether the Indication is for the same Licensed Product as has been granted Regulatory Approval but for a different Indication or for a different Licensed
Product, as follows: (i) one hundred percent (100%) of the amount in Section 3.2(a) for the [***] achievement of an event for a given Indication; and (ii) [***] percent ([***]%) of the amount in
Section 3.2(a) for the [***] achievement of an event for the same Indication. For example (and not as a limitation), if [***]. 

(c) Milestone Payment Process. Ideaya shall notify CRT within [***] days after the achievement of each milestone event described
in Sections 3.2(a). CRT shall invoice Ideaya for the amount associated with the applicable milestone event, and Ideaya shall pay CRT the applicable amount within [***] days of receipt of the undisputed invoice. Any disputes regarding an
invoice shall be resolved by the Parties promptly and in good faith. 
 (d) Ideaya Sublicense Revenue. If Ideaya exercises the
Option, Ideaya will pay to CRT the following percentage (based on the time when the sublicense was granted) of Sublicense Revenue within [***] days after Ideaya receives such Sublicense Revenue. If Ideaya does not exercise the Option, then
Ideaya will not owe Institute any payments under this Section 3.2(d). 
  

			
	 Time When Sublicense is Granted
	  	Percent of Sublicense Revenue Owed
	 [***]
	  	[***]%
	 [***]
	  	[***]%

 (e) CRT Sublicense Revenue. If this Agreement expires under
Section 10.1(a) because Ideaya did not exercise its Option, or if Institute terminates this Agreement pursuant to Section 10.2 (a) (and not 10.2 (b) or 10.2 (c), then CRT will pay to Ideaya the
following percentage (based on the time when the sublicense was granted) of Sublicense Revenue within [***] days after CRT receives such Sublicense Revenue. If this Agreement does not expire under Section 10.1(a) because
Ideaya did not exercise its Option, or if Institute does not terminates this Agreement pursuant to Section 10.2, then CRT will not owe Ideaya any payments under this Section 3.2(e). 

 

			
	 Time When Sublicense is Granted
	  	Percent of Sublicense Revenue Owed
	 [***]
	  	[***]%
	 [***]
	  	[***]%

 3.3 Royalty Payments to CRT for Net Sales of Licensed Products. If Ideaya exercises the Option,
then, subject to Section 3.4, Ideaya shall pay to CRT royalties based on the aggregate Net Sales of all Licensed Products in the Territory by or on behalf of Ideaya or its Affiliates and Sublicensees in a given
Calendar Year during the Royalty Term, on an incremental basis as set forth below. For clarity, the royalty rates set forth in the table in this Section 3.3 are intended to be applied incrementally, with the specified
royalty rate applying to the portion of Net Sales in the Territory in a given Calendar Year that fall within the range to which such royalty rate applies. If Ideaya does not exercise the Option, then Ideaya will not owe Institute any payments under
this Section 3.3. 

  
 12 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. 

Confidential treatment has been requested with respect to the omitted portions. 

			
	 Royalty Rate for Licensed Products
	  	Portion of Net Sales in the Territory in a Calendar Year
	 [***]%
	  	< £[***]
	 [***]%
	  	3 £[***]

 3.4 Royalty Reductions. 

(a) Reduced Royalty Rate for Post-Project Ideaya Patents. If a Licensed Product is covered or claimed by a Valid Claim of
the Post-Project Ideaya Patents, and not by any CRT Background IP, Joint Invention Patents or Ideaya Project IP, then the royalty-rate that Ideaya would owe to CRT pursuant to Section 3.3 for such Licensed Product will be
reduced by [***] percent ([***]%). 
 (b) Third Party Royalties for Licensed Products in the Territory. If: (i) Ideaya
has licensed rights from one or more Third Party(ies) that would be infringed but for the license if Ideaya did any of the following: Develop, Manufacture or Commercialize any Licensed Product; [***] then Ideaya may deduct from the royalties it
would otherwise owe to CRT pursuant to Section 3.3 for such Licensed Product an amount equal to [***]. 

3.5 Royalty Term. CRT’s right to receive royalties under Section 3.3 will apply on a Licensed-Product-by-Licensed Product and country-by-country basis, beginning on the First
Commercial Sale of such Licensed Product in such country and expiring upon the later to occur of the following: (a) expiration of the last Valid Claim covering or claiming the Licensed Product in such country; or (b) the tenth (10th) anniversary of such First Commercial Sale of such Licensed Product in such country (the “Royalty Term”). 

3.6 Quarterly Payments and Reports. All royalties due under Section 3.3 will be paid [***], on a country-by-country basis, within [***] days after the end of the relevant [***] for which royalties are due. Ideaya shall provide to CRT, within [***] days after the end of
each [***], a report that summarizes the Net Sales of a Licensed Product during such [***]. Such reports will also include detailed information regarding the calculation of royalties due pursuant to Section 3.3, including
allowable deductions in the calculation of Net Sales of Licensed Products on which royalties are paid. 
 3.7 Payment Method.
All payments due under this Agreement to CRT will be made by bank wire transfer in immediately available funds to an account designated by CRT. All payments hereunder will be made in Pounds. 

3.8 Taxes. Each party shall be responsible for taxes levied on any payments they are making to another Party under this
Agreement. 
 3.9 Blocked Currency. In each country where the local currency is blocked and cannot be removed from the
country, royalties accrued in that country will be placed in a local bank account on CRT’s behalf, unless otherwise mutually agreed in writing by the Parties. 

  
 13 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. 

Confidential treatment has been requested with respect to the omitted portions. 

 3.10 Sublicenses. Ideaya shall pay to CRT: (a) royalties on Net Sales
made by its Sublicensees as if such Net Sales were those of Ideaya; and (b) milestone payments pursuant to Section 3.2 based on the achievement by such Sublicensee of any milestone event contemplated in such
Section 3.2 as if such milestone event had been achieved by Ideaya. 
 3.11 Exchange Rates.
Conversion of sales recorded in local currencies to Pounds for the purposes of reporting and paying royalties to CRT will be done for each [***] on the basis of the average exchange rate for the relevant currencies across the first business day of
each month in the preceding [***]. 
 3.12 Financial Records. Ideaya and its Affiliates shall keep (and Ideaya shall procure
that its Sublicensees keep) such records as are required to determine, in a manner consistent with GAAP and this Agreement, Net Sales made on a country by country basis and the sums or credits due under this Agreement. All such books, records and
accounts shall be retained by Ideaya until the later of: (a) [***] years after the end of the period to which such books, records and accounts pertain; and (b) the expiration of the applicable tax statute of limitations (or any extensions
thereof), or for such longer period as may be required by Applicable Law. Ideaya shall require its licensees and Sublicensees to provide to Ideaya a report detailing the Net Sales expenses and calculations incurred or made by such Sublicensee, which
report will be made available to in connection with any audit conducted by CRT pursuant to Section 3.13. 

3.13 Audits. CRT will have the right to have an independent certified public accountant, reasonably acceptable to Ideaya, to
have access during normal business hours, and upon reasonable prior written notice, to examine only those records of Ideaya (and its Affiliates, licensees and Sublicensees) as may be reasonably necessary to determine, with respect to any Calendar
Year ending not more than [***] years prior to Institute’s request, the correctness or completeness of any report or payment made under this Agreement. The foregoing right of review may be exercised only [***] and only once with respect to each
such periodic report and payment. Results of any such examination will be: (a) limited to information relating to the Licensed Products; (b) made available to both Parties; and (c) subject to Article 9. CRT shall bear the full
cost of the performance of any such audit, unless such audit discloses a variance to the detriment of Ideaya of more than [***] percent ([***]%) from the amount of the original report, royalty or payment calculation, in which case Ideaya will bear
the full cost of the performance of such audit. The results of such audit will be final, absent manifest error. 
 3.14
Interest. Any undisputed payments or portions thereof due hereunder that are not paid on the date such payments are due under this Agreement will bear interest at a rate equal to the lesser of: (a) [***]; or (b) the maximum rate
permitted by law, in each case calculated on the number of days such payment is delinquent, compounded annually. 
 3.15 Payments
to or Reports by Affiliates. Any payment required under any provision of this Agreement to be made to either Party or any report required to be made by any Party will be made to or by an Affiliate of that Party if designated in writing by that
Party as the appropriate recipient or reporting entity. 

  
 14 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. 

Confidential treatment has been requested with respect to the omitted portions. 

	4.	 COLLABORATION 

4.1 Joint Research Committee. 

(a) Membership of JRC. Within [***] days after the Effective Date, each Party shall appoint [***] representatives to a joint
research committee (the “JRC”), one of which shall be that Party’s Liaison. Each Party may replace its appointed JRC representatives at any time upon prior written notice to the other Party. Each Party shall designate one
(1) of its representatives as co-chairperson of the JRC. Each of the co-chairpersons shall be responsible, on an alternating basis, with the [***] co-chairperson having responsibility with respect to the initial meeting, for working with the Liaisons to schedule meetings, prepare and circulate an agenda in advance of each meeting, and to prepare and issue
minutes of each meeting within [***] days thereafter. Any JRC member may add topics to the draft agenda. 
 (b) Responsibilities
of the JRC. The JRC shall be responsible for the Parties interacting cooperatively on conducting the Research Plan. At its meetings, the JRC shall: (i) jointly outline a strategy for conducting the Research Plan; (ii) evaluate each
Party’s progress in carrying out its obligations to conduct the Research Plan, and the data generated by each Party in conducting the Research Plan; (iii) discuss and resolve any issues related to the transfer of Transferred Technology;
and (iv) perform any other activities specifically described in this Agreement. 
 (c) JRC Decision-Making. Each
Party’s JRC representatives will collectively have a single vote, and the JRC will operate by unanimous consent of all JRC members present and in accordance with the principles set forth in Section 4.1. The JRC will
not have any authority or jurisdiction to amend, modify, or waive compliance with this Agreement, any of which shall require mutual written agreement of the Parties. If a dispute arises between the Parties’ JRC representatives, the matter will
be first referred to the Liaisons for resolution. If the Liaisons are unable to resolve the dispute, then the matter will be elevated to the Chief Executive Officer of Ideaya, the Director of the CRUK-MI on
behalf of Manchester and the Director, Business development of CRT (or, in either case, a direct report of such individual). If these three (3) individuals are unable to resolve the dispute, then, subject to the last sentence of this
Section 4.1(c), Ideaya will have the final decision, so long as such decision does not conflict with the terms of the Agreement. Notwithstanding anything to the contrary, no decision by Ideaya will: (i) require CRT or
Manchester to breach any obligation or agreement that Institute may have with or to a Third Party prior to the Effective Date; (ii) require CRT or Manchester to perform any activities that are materially different or greater in scope than those
provided for under the Agreement; or (iii) amend, modify, or waive CRT’s or Manchester’s compliance with, this Agreement, any of which shall require mutual written agreement of the Parties; or (iv) impose or increase any
financial burden on CRT or Manchester (other than any financial obligations expressly set forth in this Agreement). 
 (d)
Meetings of the JRC. During the Research Term, the JRC shall meet by audio or video teleconference twice a year, and once each Calendar Year in person (which in-person meeting shall be held on an
alternating basis in the cities of Manchester, England and in San Francisco, California, U.S., or at an agreed to location at a reasonable mid-point location). The research teams will also have periodic
research update calls as described in the Research Plan. With the consent of the representatives of each Party serving on the JRC, other representatives of each Party may attend meetings of the JRC as nonvoting observers (provided such
representatives: (i) have contractual confidentiality obligations to such Party that are at least as stringent as those set forth in this Agreement; and (ii) are under intellectual property assignment obligations to such Party). Meetings
of the JRC will be effective only if at least one (1) representative of each Party is present or participating. Each Party shall be responsible for all of its own expenses of participating in JRC meetings. The Parties shall use Reasonable
Efforts to schedule meetings of the JRC at least [***] in advance. Upon the conclusion of the Research Term, the JRC will be discontinue 

  
 15 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. 

Confidential treatment has been requested with respect to the omitted portions. 

 4.2 Liaisons. 

(a) Appointment. Within [***] days after the Effective Date, each of the Parties shall appoint an individual to act the contact
between the Parties to communicate with respect to matters under the Agreement and to assure a successful transfer of Transferred Technology (each, a “Liaison”). Each Party shall notify the other Party promptly in writing of the
identity of, and contact information for, the notifying Party’s Liaison, and each Party may change its designated Liaison from time to time upon prior written notice to the other Party. Any Liaison may designate a substitute to perform
temporarily the functions of that Liaison by written notice to the other Party. 
 (b) Responsibilities. The Liaisons will:
(i) plan and coordinate cooperative efforts and internal and external communications; (ii) coordinate the transfer of Transferred Technology; (iii) be the point of first referral in all matters of conflict resolution;
(iv) identify and bring disputes to the attention of the applicable Party in a timely manner; and (v) otherwise take responsibility for ensuring that relevant action items resulting from such Party interactions are appropriately carried
out or otherwise addressed. 
 4.3 Independence. Subject to the terms of this Agreement, the activities and resources of each
Party will be managed by such Party, acting independently and in its individual capacity. The relationship between Institute and Ideaya is that of independent contractors and neither Party will have the power to bind or obligate the other Party in
any manner. 
  

	5.	 RESEARCH, DEVELOPMENT, MANUFACTURING AND COMMERCIALIZATION 

5.1 Research, Development, and Commercialization. 

(a) During the Research Term, each Party shall use Reasonable Efforts to perform its obligations under the Research Plan. Each Party
shall bear all of its costs and expenses associated with performing its obligations under the Research Plan. 
 (b) If Ideaya
exercises its Option, then, subject to Section 5.2 and Section 5.3, Ideaya shall have sole control and responsibility for: (i) all activities directed to the Research, Development and
Commercialization of all Licensed Products; and (ii) the Manufacture, directly or with or through Third Parties, of Ideaya’s requirements of the Licensed Products. In such case, as between the Parties, Ideaya shall bear all costs and
expenses associated with activities performed by Ideaya under this Agreement. 
 5.2 Diligence and Reporting. 

(a) During the Research Term, Ideaya shall use Reasonable Efforts to: (i) Research a PARG Inhibitor; [***]. 

(b) If Ideaya exercises its Option, then Ideaya shall use Reasonable Efforts during the Term to: (i) Develop a Licensed Product
for the treatment of a cancer Indication; [***]. 

  
 16 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. 

Confidential treatment has been requested with respect to the omitted portions. 

 5.3 Institute Development Opportunity. If Ideaya exercises its Option, and
Ideaya or any of its Affiliates intends to undertake a Phase I Clinical Trial of any Licensed Product, then Ideaya shall so notify Institute in writing. Within [***] days of Institute’s receipt of such notice, [***]. 

5.4 Standards of Conduct. Each Party shall perform, or shall ensure that its Affiliates, licensees, Sublicensees and Third Party
contractors perform, all Research, Development, Manufacturing and Commercialization activities in a good scientific and ethical business manner and in compliance with the terms of this Agreement and all Applicable Law. 

 

	6.	 REGULATORY 

6.1 Ideaya’s Role. If Ideaya exercises the Option, then Ideaya shall have the sole right and responsibility for (and bear
all costs and expenses associated with): (a) all regulatory activities regarding Licensed Products; (b) pharmacovigilance for such Licensed Product; and (c) conducting all pricing and reimbursement approval proceedings relating to each
Licensed Product in the Territory. 
 6.2 Ownership of Regulatory Filings. Ideaya will own all regulatory filings for Licensed
Products made after the Option Exercise Date. Ideaya shall prepare and draft all such filings (including any supplements or modifications thereto and including the preparation of any electronic submission of a Regulatory Approval Application) to
Regulatory Authorities in each such country for such Licensed Product. CRT shall cooperate with Ideaya as reasonably necessary to file for and/or maintain any orphan designations and other regulatory exclusivities for Licensed Products in the
Territory. 
 6.3 Recalls in the Territory. If Ideaya exercises the Option, then any decision to initiate a recall or
withdrawal of a Licensed Product in the Territory shall be made by Ideaya. In the event of any such recall or withdrawal, Ideaya shall take any and all necessary action to implement such recall or withdrawal in accordance with Applicable Law. The
costs of any such recall or withdrawal in the Territory shall be borne solely by Ideaya. 
  

	7.	 TRANSFER OF KNOW-HOW 

7.1 Transferred Technology. Within [***] days after the Effective Date, CRT shall provide to Ideaya all Transferred Technology
existing as of the Effective Date. Additionally, within [***] days after the Option Exercise Date, Institute shall provide to Ideaya any additional Transferred Technology that CRT is aware of. Furthermore, Institute shall provide a reasonable amount
of on-site advice or support in connection with the foregoing transfers, as requested in writing by Ideaya, and Ideaya shall reimburse Institute for reasonable travel costs incurred in connection therewith.

 7.2 Know-How Assistance. During the first [***] after the Option Exercise Date,
resources permitting and by prior arrangement with Manchester, Ideaya may consult with applicable Manchester employees having experience with Licensed Products, on a reasonable basis, [***]. All such consultations will occur at mutually agreeable
times and places. Ideaya shall reimburse Manchester for any reasonable out-of-pocket costs or expenses (such as needed transportation and lodging costs, if requested by
Ideaya) that Manchester incurs in connection with such consultations and that are pre-approved by Ideaya in writing. 

  
 17 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. 

Confidential treatment has been requested with respect to the omitted portions. 

	8.	 PATENT PROSECUTION AND ENFORCEMENT 

8.1 Ownership. 

(a) The inventorship of all Sole Inventions and Joint Inventions will be determined in accordance with the U.S. patent law. 

(b) Each Party will own the entire right, title and interest in and to any and all of its Sole Inventions, and Patents claiming only
such Sole Inventions invented by such Party (“Sole Invention Patents”). Ideaya and CRT will be joint owners in and to any and all Joint Inventions and Patents claiming such Joint Inventions (“Joint Invention
Patents”). Subject to the licenses to Ideaya and other provisions of this Agreement, and the other terms and conditions of this Agreement, (i) Ideaya and CRT as joint owners will each have the right to exploit, to grant licenses under,
to assign and to otherwise dispose of such Joint Inventions, without accounting or obligation to, or consent required from, the other Party and (ii) each Party grants to the other Party a nonexclusive, fully-paid, royalty-free, irrevocable,
perpetual license (sublicensable through multiple tiers) under the Joint Invention Patents to make, use, sell, offer for sale and import inventions claimed in the Joint Invention Patents, except for those licensed to Ideaya on an exclusive basis
pursuant to this Agreement. 
 (c) All employees, agents and contractors of each Party shall be bound by written obligation to assign
any inventions and related intellectual property to the Party for whom they are employed or are providing services. 
 (d) The
Parties acknowledge and agree that this Agreement will be deemed to be a “Joint Research Agreement” as defined under 35 U.S.C. 103(c), and that all Inventions are intended to have the benefit of the rights and protections conferred by the
Cooperative Research and Enhancement Act of 2004 (the “CREATE Act”). In the event that a Party seeks to rely on the foregoing and to invoke the CREATE Act with respect to any Invention, such Party will give prior written notice to the
other Party of its intent to invoke the CREATE Act and of each submission or disclosure such Party intends to make to the United States Patent and Trademark Office (the “USPTO”) pursuant to the CREATE Act, including: (i) any
disclosure of the existence or contents of this Agreement to the USPTO, (ii) the disclosure of any “subject matter developed by the other Party” (as such term is used in the CREATE Act) in an information disclosure statement or
otherwise, or (iii) the filing of any terminal disclaimer over the intellectual property of the other Party, it being agreed that no such submission, disclosure or filing shall be made by such Party without the prior written consent of the
other Party, such consent not to be unreasonably withheld, conditioned or delayed, except that no such consent shall be required to disclose to the USPTO, through an information disclosure statement or otherwise, any “subject matter developed
by the other Party” that was previously published or included in a Patent Application by the other Party. The other Party will provide reasonable cooperation to such Party in connection with such Party’s efforts to invoke and rely on the
CREATE Act. 
 8.2 Disclosure. Each Party shall submit a written report to the other Party, no less frequently than within
[***] days after the end of each [***], describing any Joint Invention arising during the prior [***] in the course of the Agreement which it believes may be patentable or at such earlier time as may be necessary to preserve patentability of such
invention. Manchester and CRT shall provide [***] to Ideaya such assistance and execute such documents as are reasonably necessary to permit the filing and prosecution of such patent application to be filed on such Joint Invention, or the issuance,
maintenance, extension or assignment of any resulting Patent. 

  
 18 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. 

Confidential treatment has been requested with respect to the omitted portions. 

 8.3 Patent Prosecution and Maintenance; Abandonment. 

(a) Prosecution and Maintenance. 

(i) Filing, Prosecution and Maintenance Before Option Exercise. Subject to Section 8.3(a)(ii) and
Section 8.3(a)(iii), after the Effective Date and before Ideaya’s exercise of the Option: (A) CRT shall at Ideaya’s sole cost be responsible for the preparation, filing, prosecution and maintenance (including the
handling of any inter partes review, post grant review, ex parte reexamination, supplemental examination, opposition and similar proceedings) of all Patents that are included in the CRT Background IP (the “CRT Background Patents”),
subject to Ideaya’s review and direction, and Ideaya shall reimburse CRT for any and all out-of-pocket costs and expenses within [***] days of an invoice issued by
CRT; and (B) Ideaya shall be responsible for the preparation, filing, prosecution and maintenance (including the handling of any inter partes review, post grant review, ex parte reexamination, supplemental examination, opposition and similar
proceedings) of all Patents covering or claiming Ideaya Project IP and/or any Joint Invention Patents (the “PARG Program Patents”), each of CRT and Ideaya, the “Prosecuting Party” with respect to the applicable
Patents; provided that such responsibilities be carried out by external patent counsel selected by the Prosecuting Party, or by the Prosecuting Party’s internal patent counsel in conjunction with external patent counsel selected by the
Prosecuting Party. The Prosecuting Party, or its external counsel, shall provide the other Party with a written update of the filing, prosecution and maintenance status for each of the CRT Background Patents and the PARG Program Patents on a [***]
basis (as applicable), and the Prosecuting Party (or its external counsel) shall provide the other Party with drafts of proposed filings (including the initial application and an material correspondence related to such filing) to permit such other
Party a reasonable opportunity for review and comment before such filings are due. The other Party shall provide any comments to the Prosecuting Party at least [***] Business Days prior to the original response deadlines that are required for such
filing (without regard to applicable extensions). In the absence of a response from such other Party, the Prosecuting Party may submit such proposed filing in keeping with the terms of this Agreement. The Prosecuting Party shall also provide a copy
all office actions and responses to office actions to the other Party. 
 (ii) Filing, Prosecution and Maintenance After Option
Exercise. If Ideaya exercises the Option before the expiration of the Option Period, then: (A) the CRT Background Patents shall be included as part of the PARG Program Patents; and (B) Ideaya shall be responsible for, and have sole
control over, the preparation, filing, prosecution and maintenance (including the handling of any inter partes review, post grant review, ex parte reexamination, supplemental examination, opposition and similar proceedings) of all PARG Program
Patents pursuant to the procedures described in Section 8.3(a)(i). If Ideaya does not exercise the Option before the expiration of the Option Period, then, subject to Section 8.3(a)(iv), CRT shall after
consulting with Ideaya be responsible for, and have sole control over, the preparation, filing, prosecution and maintenance (including the handling of any inter partes review, post grant review, ex parte reexamination, supplemental examination,
opposition and similar proceedings) of all PARG Program Patents. 
 (iii) Abandonment by Ideaya. If Ideaya decides to
discontinue the prosecution or maintenance of a Patent within the PARG Program Patents in any country, Ideaya shall provide CRT with notice of this decision at least [***] days prior to any pending lapse or abandonment thereof, and CRT will
thereafter have the right to take over sole ownership and to assume responsibility for the filing, prosecution and maintenance of such Patent or patent application by so notifying Ideaya in writing. If CRT assumes such responsibility for such
filing, prosecution and maintenance, then: (A) Ideaya shall cooperate as reasonably requested by CRT to facilitate control of such filing, prosecution and maintenance by CRT; and (B) such abandoned Patent will no longer be subject to the
licenses in Section 2.4. 

  
 19 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. 

Confidential treatment has been requested with respect to the omitted portions. 

 (iv) Abandonment by Institute. If CRT decides to discontinue the prosecution
or maintenance of a Patent within PARG Program Patents in any country, CRT shall provide Ideaya with notice of this decision at least [***] days prior to any pending lapse or abandonment thereof, and Ideaya will thereafter have the right to take
over sole ownership and to assume responsibility for the filing, prosecution and maintenance of such Patent or patent application by so notifying CRT in writing. If Ideaya assumes such responsibility for such filing, prosecution and maintenance,
then: (A) [***]; (B) CRT shall assist and shall cooperate as reasonably requested by Ideaya to facilitate control of such filing, prosecution and maintenance by Ideaya; and (C) and Ideaya will be subject to any payment obligations under
Article 3 for Licensed Products covered by such abandoned Patent. 
 (b) Payment of Prosecution Costs. 

(i) Ideaya Payment. Ideaya shall pay the expenses associated with the filing, prosecution (including any interferences, reissue
proceedings, reexaminations and oppositions) and maintenance of any PARG Program Patents prosecuted by Ideaya or by CRT under Section 8.3(a)(i), (ii) and (iv). 

(ii) Institute Payment. Institute shall pay the expenses associated with the filing, prosecution (including any interferences,
reissue proceedings, reexaminations and oppositions) and maintenance of any PARG Program Patents prosecuted by CRT under Section 8.3(a) (iii). 

8.4 Enforcement of Patent Rights and Know-How. If either Party becomes aware of a
suspected infringement of any PARG Program Patents, or the misappropriation by a Third Party of any Know-How, through the development, manufacture or sale of a Licensed Product by a Third Party, such Party
shall notify the other Party promptly, and following such notification, the Parties shall confer. If Ideaya exercises the Option before the expiration of the Option Period, then Ideaya will have the first right, but will not be obligated, to bring
an infringement or misappropriation action against such Third Party at its own expense and by counsel of its own choice, and Institute will have the right to participate in such action, at its own expense and by counsel of its own choice. If Ideaya
does not exercise the Option before the expiration of the Option Period, then Institute will have the first right, but will not be obligated, to bring an infringement or misappropriation action against such Third Party at its own expense and by
counsel of its own choice, and Ideaya will have the right to participate in such action, at its own expense and by counsel of its own choice. If the Party with the first right to enforce fails to bring such an action prior to the earlier of: (a)
[***] days following the Parties’ receipt of notice of alleged infringement or misappropriation; or (b) [***] days before the time limit, if any, set forth in the Applicable Law for the filing of such action, the other Party will have the right
to bring and control any such action, at its own expense and by counsel of its own choice, and the Party with the first right to enforce will have the right to be represented in any such action, at its own expense and by counsel of its own choice.
If a Party brings an infringement or misappropriation action pursuant to this Section 8.4, the other Party will reasonably assist the enforcing Party (at the enforcing Party’s expense) in such actions or proceedings if
so requested, and such other Party will lend its name to such actions or proceedings if necessary under Applicable Law for the enforcing Party to bring such action. Neither Party will have the right to settle any patent infringement or
misappropriation litigation under this Section 8.4 in a manner that diminishes the rights or interests of the other Party without the prior written consent of such other Party, such consent not to be unreasonably withheld,
delayed or conditioned. Except as otherwise agreed to by the Parties 

  
 20 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. 

Confidential treatment has been requested with respect to the omitted portions. 

 
as part of a cost sharing arrangement, any recovery realized as a result of such litigation, after pro rata reimbursement of any litigation expenses of Ideaya and Institute, will either be
allocated to Ideaya and treated as [***] (if Ideaya is the Party bringing such litigation) or will be allocated to Institute and treated as [***] (if Institute is the Party bringing such litigation). 

8.5 Data Exclusivity and Orange Book Listings. If Ideaya exercises the Option before the expiration of the Option Period, then
Ideaya will have the sole right to seek, maintain and enforce all data exclusivity periods available for the Licensed Products (such as those periods listed in the FDA’s Orange Book and all international equivalents), and CRT shall reasonably
cooperate with Ideaya in filing and maintaining such Orange Book (and international equivalent) listings. If Ideaya does not exercise the Option before the expiration of the Option Period, then CRT will have the sole right to seek, maintain and
enforce all data exclusivity periods available for the Licensed Products (such as those periods listed in the FDA’s Orange Book and all international equivalents), and Ideaya shall reasonably cooperate with CRT in filing and maintaining such
Orange Book (and international equivalent) listings 
 8.6 Patent Term Extension. If Ideaya exercises the Option before the
expiration of the Option Period, CRT shall cooperate with any of Ideaya’s efforts to obtain patent term extension or supplemental protection certificates or their equivalents in any country with respect to Patents covering the Licensed
Products. If Ideaya does not exercise the Option before the expiration of the Option Period, Ideaya shall cooperate with any of CRT’s efforts to obtain patent term extension or supplemental protection certificates or their equivalents in any
country with respect to Patents covering the Licensed Products. 
 8.7 Defense of Third Party Claims. If a claim is brought by
a Third Party that any Licensed Product under the Agreement infringes the intellectual property rights of such Third Party, each Party shall give prompt written notice to the other Party of such claim, and following such notification, the Parties
shall confer on how to respond. 
  

	9.	 CONFIDENTIALITY 

9.1 Nondisclosure of Confidential Information. Subject to Section 9.2, all Information disclosed by any
Party to the other Party pursuant to this Agreement shall be treated as “Confidential Information” of the disclosing Party for all purposes hereunder. The terms of this Agreement will be the Confidential Information of both Parties.
The Parties agree that during the period from the Effective Date through the Term, and for a period of [***] years thereafter, a Party receiving Confidential Information of the other Party shall: (a) use Reasonable Efforts to maintain in
confidence such Confidential Information (but not less than those efforts as such Party uses to maintain in confidence its own proprietary industrial information of similar kind and value) and not to disclose such Confidential Information to any
Third Party without prior written consent of the other Party (such consent not to be unreasonably withheld, delayed or conditioned), except for disclosures made in confidence to any Third Party under terms consistent with this Agreement; and
(b) not use such other Party’s Confidential Information for any purpose except those permitted by this Agreement (it being understood that this Section 9.1 will not create or imply any rights or licenses not
expressly granted under Article 2, and it is also understood that, upon termination of this Agreement, a Party’s right to use the Confidential Information of the other Party will cease, except as expressly permitted under
Section 10.4). 

  
 21 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. 

Confidential treatment has been requested with respect to the omitted portions. 

 9.2 Exceptions. The obligations in Section 9.1 will
not apply with respect to any portion of the Confidential Information that the receiving Party can show by competent written proof: 

(a) is publicly disclosed by the disclosing Party, either before or after it is disclosed to the receiving Party hereunder; 

(b) was known to the receiving Party or any of its Affiliates, without obligation to keep it confidential, prior to disclosure by the
disclosing Party, as shown by Recipient’s files and records prior to the date of disclosure; 
 (c) is subsequently disclosed to
the receiving Party or any of its Affiliates by a Third Party lawfully in possession thereof and without obligation to keep it confidential; 

(d) is published by a Third Party or otherwise becomes publicly available or enters the public domain, either before or after it is
disclosed to the receiving Party, and is not directly or indirectly supplied by the receiving Party in violation of this Agreement; or 

(e) has been independently developed by employees or contractors of the receiving Party or any of its Affiliates without the aid,
application or use of the disclosing Party’s Confidential Information. 
 9.3 Authorized Disclosure. A Party may disclose
the Confidential Information disclosed by another Party to the extent such disclosure is reasonably necessary in the following instances; provided that notice of any such disclosure will be sent as soon as practicable to the other Party: 

(a) during the Term, when filing or prosecuting Patents covering Sole Inventions, Joint Inventions or Licensed Products, in each case
pursuant to activities under this Agreement; 
 (b) during the Term, when making regulatory filings for Licensed Products; 

(c) during the Term, when disclosed by Institute to any reviewers of the Institute’s grant funding, under conditions of
confidentiality equivalent to those included in this Agreement; 
 (d) when prosecuting or defending litigation; 

(e) when complying with applicable governmental laws and regulations or complying with the requirements of the national securities
exchanges or other stock markets on which such Party’s securities are traded; and 
 (f) when disclosing to a receiving
Party’s Affiliates; potential or actual collaborators, partners, and licensees (including potential co-marketing and co-promotion contractors); potential or actual
investment bankers, acquirers, lenders or investors; employees; consultants; and agents, each of whom, prior to disclosure, must be bound by similar obligations of confidentiality and non-use as set forth in
this Article 9. For clarity, a confidentiality and non-use period of [***] years will be sufficient. 

  
 22 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. 

Confidential treatment has been requested with respect to the omitted portions. 

 9.4 Termination of Prior Agreements. As of the Effective Date, this Agreement
terminates the confidential disclosure agreement that is between Institute and Ideaya and that is effective as of [***] (such confidential disclosure agreement, as may be amended, the “Prior CDA”). All confidential
information exchanged between the Parties with respect to Licensed Products under the Prior CDA will be deemed Confidential Information and will be subject to the terms of this Article 9. Publicity. Any publication, news release or other
public announcement relating to the execution of this Agreement will first be reviewed and approved by both Parties; and CRT will delay any announcement to enable any securities filing that is required by Applicable Law, including disclosures
required by the U.S. Securities and Exchange Commission, or made pursuant to the requirements of the national securities exchange or other stock market on which such Ideaya’s securities are traded, pursuant to
Section 9.6. 
 9.5 Securities Filings. If a Party is required by Applicable Law to make a
securities filing relating to the execution of this Agreement with the appropriate governmental authorities (including the U.S. Securities and Exchange Commission, and any securities exchange on which securities of such Party are listed), then the
Party under such requirement shall prepare a draft of such securities filing for review and comment by the other Party. If such securities filing includes the disclosure of this Agreement and its terms, the Party under such disclosure obligation
shall include a confidential treatment request and a proposed redacted version of this Agreement as part of such draft. Such draft securities filing will, where practicable, be provided to the other Party reasonably in advance of the deadline for
such securities filing, and the other Party agrees to promptly (and in any event, no less than [***] days (or such shorter time to meet any filing deadline where it was not practical to provide the other Party with [***] days’ notice) after
receipt of such confidential treatment request and proposed redactions) give its input in a reasonable manner in order to allow the Party seeking disclosure to file its request within the timelines proscribed by the regulations of applicable
governmental authorities or securities exchange. The Party seeking such disclosure shall use Reasonable Efforts to obtain confidential treatment of this Agreement from the applicable governmental authority or securities exchange as represented by
the redacted version reviewed by the other Party. 
 9.6 Publications. Subject to Section 9.3 and
Section 9.6 (for securities filings), each Party shall permit the other Party to review any proposed disclosure that contains Confidential Information of the other Party and that would or may constitute an oral, written or
electronic public disclosure if made (including the full content of proposed abstracts, manuscripts or presentations) relating to Licensed Products or which otherwise may contain Confidential Information, at least [***] days prior to its intended
submission for publication and agrees, upon request, not to submit any such abstract or manuscript for publication until the other Party is given an additional [***] day period to secure patent protection for any material in such publication which
it believes to be patentable. Both Parties understand and agree that a reasonable commercial strategy may require delay of publication of information or filing of patent applications. The Liaisons (or the Parties), as appropriate, will review such
requests and recommend subsequent action. Subject to Section 9.3 and Section 9.6 (for securities filings), neither Party will have the right to publish or present Confidential Information of
the other Party which is subject to Section 9.1. Nothing contained in this Section 9.7 will prohibit the inclusion of Confidential Information of the
non-filing Party necessary for a patent application, provided the non-filing Party is given a reasonable opportunity to review the extent and necessity for its
Confidential Information to be included prior to submission of such patent application related to the Agreement. Any disputes between the Parties regarding delaying a publication or presentation to permit the filing of a patent application will be
referred to the JRC Decision Making process as described in Section 4.1(c). [***] within CRT Background IP, Ideaya Project IP and Joint Inventions will not be published or presented publicly, or disclosed to any outside party in any fashion,
including under confidentiality, without the prior written approval of [***]. 

  
 23 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. 

Confidential treatment has been requested with respect to the omitted portions. 

	10.	 TERM AND TERMINATION 

10.1 Term. This Agreement will become effective on the Effective Date and will remain in effect until: (a) the end of the
Option Period (if Ideaya does not exercise its Option); or (b) the expiration of all payment obligations under Article 3 (if Ideaya exercises its Option), in either case unless earlier terminated in accordance with
Section 10.2 or by mutual written agreement of the Parties (the “Term”). If Ideaya exercises its Option, then, upon the expiration of the Term with respect to a Licensed Product in a country, Ideaya will
have a fully-paid, perpetual license under Section 2.4 to Research, Develop, Manufacture, use, sell, offer for sale, have sold, distribute, import, export and otherwise Commercialize Licensed Products in the Field in such
country. 
 10.2 Termination Provisions. 

(a) Termination for Uncured Material Breach. If a Party believes that another is in material breach of this Agreement (including
any material breach of a representation or warranty made in this Agreement), then the non-breaching Party may deliver notice of such breach to the other Party. In such notice the
non-breaching Party acting reasonably will identify the actions or conduct that such Party would consider as an acceptable cure of such breach. The allegedly breaching Party shall have thirty (30) days to
cure such breach, except that, if the allegedly breaching Party disputes in good faith the existence of a material breach, the thirty (30) day cure period will be tolled until such time as the dispute is resolved by the Parties pursuant to
Section 13.1. If the Party receiving notice of breach fails to cure such breach within the thirty (30) day period (as may be tolled by the foregoing sentence), then the Party originally delivering the notice may
terminate this Agreement by providing at least thirty (30) days advance written notice to all other Parties including the allegedly breaching Party (the “Subsequent Termination Notice”). 

(b) Insolvency. If a Party (the “Insolvent Party”): (i) becomes insolvent, or institutes or has instituted
against it a petition for bankruptcy or is adjudicated bankrupt; (ii) executes a bill of sale, deed of trust, or a general assignment for the benefit of creditors; (iii) is dissolved; or (iv) a receiver is appointed for the benefit of
its creditors, or a receiver is appointed on account of insolvency; then the Insolvent Party will immediately notify the other Parties in writing of such event, and such condition will be ground for termination of this Agreement under
Section 10.2(a). 
 (c) Termination by Institute Regarding Tobacco Party. CRT and Manchester will
have the right to terminate this Agreement by providing at least thirty (30) days advance written notice to Ideaya if Ideaya becomes an Affiliate of a Tobacco Party, or if any of Ideaya’s rights and obligations are transferred to a Tobacco
Party, at the end of which period the termination will be effective. 
 10.3 Survival; Effect of Termination. 

(a) In the event of termination of this Agreement, the following provisions of this Agreement will survive for the maximum period
permitted under Applicable Law: Articles 1, 8, 9, 12 and 13; Sections 3.12, 10.1, 10.3, 10.4, and any Sections referenced within the foregoing Articles or Sections. 

(b) In any event, termination of this Agreement will not: (i) relieve the Parties of any liability which accrued hereunder prior
to the effective date of such termination; (ii) preclude either Party from pursuing all rights and remedies it may have hereunder or at law or in equity with respect to any breach of this Agreement; or (iii) prejudice either Party’s
right to obtain performance of any obligation. 

  
 24 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. 

Confidential treatment has been requested with respect to the omitted portions. 

 10.4 Licenses and Rights on Termination. 

(a) Termination under Section 10.2 by Institute. If this Agreement expires under
Section 10.1(a) because Ideaya did not exercise its Option, or if Institute terminates this Agreement pursuant to Section 10.2, then: (i) the licenses granted to Ideaya under
Section 2.4 will terminate; and (ii) Ideaya shall, and hereby does, grant to Institute an exclusive, worldwide, Sublicense Revenue-bearing license (as described in Section 3.2(e)), with the
right to grant sublicenses, under the Ideaya Project IP and under Ideaya’s interest in any Joint Invention Patents to Research, Develop, Manufacture, use, sell, offer for sale, have sold, distribute, import, export and otherwise Commercialize
Licensed Products in the Field in the Territory. In circumstances where the license to CRT under this Section 10.4(a) arises, CRT may at any time require Ideaya Project IP to be [***]. 

(b) Termination under Section 10.2(a) by Ideaya. If Ideaya terminates this Agreement pursuant to
Section 10.2(a) because CRT or Manchester is the breaching Party, then Ideaya’s licenses under Section 2.4(b) shall survive, and any amounts owed by Ideaya to CRT under Article 3 shall
be reduced by [***] percent ([***]%). For avoidance of doubt, Article 3 will also survive in this circumstance. 
  

	11.	 REPRESENTATIONS AND WARRANTIES AND COVENANTS 

11.1 Mutual Authority. Institute and Ideaya each represents and warrants to the other Party as of the Effective Date that:
(a) it has the authority and right to enter into and perform this Agreement; (b) this Agreement is a legal and valid obligation binding upon it and is enforceable in accordance with its terms, subject to applicable limitations on such
enforcement based on bankruptcy laws and other debtors’ rights; and (c) its execution, delivery and performance of this Agreement will not conflict in any material fashion with the terms of any other agreement or instrument to which it is
or becomes a party or by which it is or becomes bound, nor violate any law or regulation of any court, governmental body or administrative or other agency having authority over it. 

11.2 Institute Representations and Warranties. CRT and Manchester respectively represent and warrant severally and not jointly
to Ideaya that as at the Effective Date, as far as they are aware: 
 (a) [***] 

(b) [***] 
 (c)
[***] 
 (d) [***] 

(e) [***] 
 (f)
[***]. 
 11.3 Performance by Affiliates. The Parties recognize that each Party may perform some or all of its obligations
under this Agreement through such Party’s Affiliates. 

  
 25 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. 

Confidential treatment has been requested with respect to the omitted portions. 

	12.	 INDEMNIFICATION AND LIMITATION OF LIABILITY 

12.1 Indemnification by Ideaya. Subject to Section 12.2, Ideaya shall indemnify, defend and hold
harmless Institute, its Affiliates, and their respective directors, employees and agents (“Institute Indemnitees”) from and against any and all Third Party suits, claims, actions, demands, liabilities, threatened damages, expenses
or losses, including reasonable legal expenses and reasonable attorneys’ fees, (collectively, “Losses”) to the extent such Losses arise or result from: (a) the Development, Manufacture, use, handling, storage, sale or
other Commercialization of Licensed Products by Ideaya or its Affiliates, agents or Sublicensees; or (b) negligence, gross negligence, willful misconduct or breach of this Agreement (including of any representation or warranty) by an Ideaya
Indemnitee, except to the extent such Losses arise or result from the negligence, gross negligence, willful misconduct or breach of this Agreement by an Institute Indemnitee. 

If Ideaya exercises the Option, then Ideaya shall procure and maintain throughout the Term insurance from a reputable insurer in respect of
all risks that it would be prudent to insurer against in respect of its potential liability and for an amount that is reasonably sufficient to cover Ideaya’s potential liability, under this Section 12.1 and provide a
copy of the insurance policy and evidence of the premium paid upon receipt of written request by CRT from time to time. 
 12.2
Conditions to Indemnification, Defense and Hold Harmless Obligations. As used herein, “Indemnitee” will mean a Party entitled to rights under the terms of Section 12.1. As conditions precedent to
each Indemnitee’s right to seek indemnification, holding harmless or defense under Section 12.1 is that such Indemnitee shall: 

(a) inform the indemnifying Party under Section 12.1 of a Loss as soon as reasonably practicable after it
receives notice of the Loss; 
 (b) if the indemnifying Party acknowledges that such Loss falls within the scope of its obligations
hereunder, permit the indemnifying Party to assume direction and control of the defense, litigation, settlement, appeal or other disposition of the Loss (including the right to settle the claim solely for monetary consideration); on the condition
that the indemnifying Party will seek the prior written consent (such consent not to be unreasonably withheld, delayed or conditioned) of any such Indemnitee as to any settlement which would: (i) materially diminish or materially adversely
affect the scope, exclusivity or duration of any Patents licensed under this Agreement; (ii) require any payment by such Indemnitee; (iii) require an admission of legal wrongdoing in any way on the part of an Indemnitee; or (iv) amend
this Agreement; and 
 (c) fully cooperate (including providing access to and copies of pertinent records and making available for
testimony relevant individuals subject to its control) as reasonably requested by, and at the expense of, the indemnifying Party in the defense of the Loss. 

If an Indemnitee has complied with all of the conditions described in Sections 12.2(a) – (c), as applicable, the indemnifying Party
shall supply attorneys reasonably acceptable to the Indemnitee at the indemnifying Party’s cost to defend against any such Loss. Subject to the foregoing, an Indemnitee may participate in any proceedings involving such Loss using attorneys of
the Indemnitee’s choice and at the Indemnitee’s expense. In no event may an Indemnitee settle or compromise any Loss for which the Indemnitee intends to seek indemnification from the indemnifying Party hereunder without the prior written
consent of the indemnifying Party (such consent not to be unreasonably withheld, delayed or conditioned), or the indemnification under Section 12.1 as to such Loss will be null and void. 

  
 26 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. 

Confidential treatment has been requested with respect to the omitted portions. 

 12.3 Limitation of Liability. EXCEPT FOR A PARTY’S OBLIGATIONS UNDER
SECTIONS 12.1, AND EXCEPT FOR BREACH OF ARTICLE 9, IN NO EVENT WILL EITHER PARTY, ITS DIRECTORS, OFFICERS, EMPLOYEES, AGENTS OR AFFILIATES BE LIABLE TO THE OTHER PARTY FOR ANY LOST PROFIT, INDIRECT, INCIDENTAL, SPECIAL, PUNITIVE,
EXEMPLARY OR CONSEQUENTIAL DAMAGES, WHETHER BASED UPON A CLAIM OR ACTION OF CONTRACT, WARRANTY, NEGLIGENCE, STRICT LIABILITY OR OTHER TORT, OR OTHERWISE, ARISING OUT OF THE AGREEMENT. 

Provided that nothing in this Agreement shall be construed as excluding or limiting the liability of any Person for any liability which cannot
be limited or excluded by Applicable Law, and without prejudice to CRT’s obligation to make payments to Ideaya pursuant to Section 3.2(e), in no event shall the liability of CRT or Manchester in aggregate under this
Agreement exceed [***] Pounds (£[***]) in aggregate for any and all claims, on the condition that, for any liability amounts of CRT or Manchester in excess of [***] Pounds (£[***]) (“Excess Liability Amounts”), [***].

  

	13.	 MISCELLANEOUS 

13.1 Dispute Resolution. 

(a) Except for any dispute described in Section 13.3 (which shall be handled exclusively in accordance with
Section 13.3), if any dispute, controversy or claim arises out of, relates to or connects with any provision of the Agreement (each, a “Disputed Matter”), the Parties shall try to settle the Disputed Matter
using informal dispute resolution via the JRC, and by referring the Disputed Matter to the Party’s respective Executive Officers. Either Party may initiate such informal dispute resolution by sending written notice of the dispute to the other
Party, and, within [***] days after such notice, such Executive Officers shall meet for attempted resolution by good faith negotiations. If such Executive Officers are unable to resolve such Disputed Matter within [***] days after their first
meeting for such negotiations, the Parties shall resolve their dispute using binding arbitration under Section 13.1(b). 

(b) If the Parties are unable to resolve a Disputed Matter using the process described in Section 13.1(a),
then a Party seeking further resolution of the Disputed Matter shall submit the Disputed Matter to resolution by final and binding arbitration administered by the [***] in accordance with its arbitration rules, (the “Rules”), except
as otherwise provided herein and applying the substantive law specified in Section 13.2. Whenever a Party decides to institute arbitration proceedings, it shall give written notice to that effect to the other Party, and the
place of arbitration will be in London, England. The arbitration will be conducted by a panel of three (3) arbitrators, who will be appointed as follows: each Party will appoint a single arbitrator, and the two (2) arbitrators will
agree on a third (3rd) arbitrator who will act as the chair of the arbitral tribunal, within [***] days after their appointment. If the two (2) arbitrators are unable to agree on the third (3rd) arbitrator within such [***] days, then the third (3rd) arbitrator will be appointed by the [***] in accordance with the Rules. Each arbitrator
must be in business/practicing in his field and have business or legal experience in the biotechnology or pharmaceutical industry of not less than ten years. The arbitrators will not have the power to award damages excluded pursuant to
Section 12.4, and any arbitral award that purports to award such damages is expressly prohibited and void ab initio. Decisions of the arbitrators 

  
 27 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. 

Confidential treatment has been requested with respect to the omitted portions. 

 
that conform to the terms of this Section 13.1(b) will be final and binding on the Parties, and judgment on the award so rendered may be entered in any court of
competent jurisdiction. The losing Party, as determined by the arbitrators, shall pay all of the administrative costs and fees of the arbitration and the fees and costs of the arbitrator, and the arbitrators will be directed to provide for payment
or reimbursement of such fees and costs by the losing Party. If the arbitrators determine that there is no losing Party, the Parties shall each bear or pay one-half (1/2) of those costs and fees and the
arbitrator’s award will so provide. Notwithstanding the foregoing, each Party shall bear or pay its own attorneys’ fees, expert or witness fees, and any other fees and costs, and no such fees or costs will be shifted to the other Party.
Except as may be required by Applicable Law, no Party (or its representative, witnesses or arbitrators) may disclose the existence, content or result of any arbitration under this Agreement without the prior written consent of both Parties, except
that no such consent will be required to enter and enforce the judgment in court. 
 13.2 Governing Law. Resolution of all
disputes, controversies or claims arising out of, relating to or in connection with the Agreement or the performance, enforcement, breach or termination of the Agreement and any remedies relating thereto, will be governed by and construed under
English law, to the exclusion of the UN Convention on Contracts for the International Sale of Goods, except as described in Section 8.1(a). 

13.3 Patents and Trademarks; Equitable Relief. 

(a) Any dispute, controversy or claim arising out of, relating to or in connection with: (i) the scope, validity, enforceability or
infringement of any Patent rights; or (ii) any trademark rights related to any Licensed Product, shall in each case be submitted to a court of competent jurisdiction in the territory in which such Patent or trademark rights were granted or
arose. 
 (b) Any dispute, controversy or claim arising out of, relating to or in connection with the need to seek preliminary or
injunctive measures or other equitable relief (e.g., in the event of a potential or actual breach of the confidentiality and non-use provisions in Article 9) need not be resolved through the procedure
described in Section 13.1 but may be immediately brought in a court of competent jurisdiction. 
 13.4
Entire Agreement. This Agreement, together with the Exhibits attached hereto, sets forth the complete, final and exclusive agreement and all the covenants, promises, agreements, warranties, representations, conditions and understandings
between the Parties hereto and supersedes and terminates all prior agreements and understandings between the Parties. There are no covenants, promises, agreements, warranties, representations, conditions or understandings, either oral or written,
between the Parties other than as are set forth herein and therein. 
 13.5 Export Control. This Agreement is made subject to
any restrictions concerning the export of products or technical information from the U.S. or other countries which may be imposed upon or related to Institute or Ideaya from time to time. Each Party agrees that it will not export, directly or
indirectly, any technical information acquired from the other Party under this Agreement or any products using such technical information to a location or in a manner that at the time of export requires an export license or other governmental
approval, without first obtaining the written consent to do so from the appropriate agency or other governmental entity. 

  
 28 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. 

Confidential treatment has been requested with respect to the omitted portions. 

 13.6 Force Majeure. Each Party will be excused from the performance of its
obligations under this Agreement to the extent that such performance is prevented by Force Majeure, and the nonperforming Party promptly provides notice of the prevention to the other Party. Such excuse will be continued so long as the condition
constituting Force Majeure continues and the nonperforming Party takes reasonable efforts to remove the condition. For purposes of this Agreement, “Force Majeure” will include conditions beyond the control of the Parties, including
an act of God, acts of terrorism, voluntary or involuntary compliance with any regulation, law or order of any government, war, civil commotion, labor strike or lock-out, epidemic, failure or default of public
utilities or common carriers, destruction of production facilities or materials by fire, earthquake, storm or like catastrophe. 

13.7 Notices. Any notices given under this Agreement shall be in writing, addressed to the Parties at the following addresses,
and delivered by person, by facsimile (with receipt confirmation), by email (with confirmation by an email sent to the sender or by a notice delivered by another method in accordance with this Section 13.7, except that
automated replies and “read receipts” shall not be considered confirmation of receipt), or by FedEx or other reputable courier service. Any such notice will be deemed to have been given: (a) as of the day of personal delivery;
(b) one (1) day after the date sent by confirmed facsimile or confirmed email; or (c) on the day of successful delivery to the other Party confirmed by the courier service. Unless otherwise specified in writing, the mailing addresses of
the Parties will be as described below. 
  

					
		  	For Institute:	  	 Cancer Research Technology Ltd.

Angel Building, 407 St John Street

London EC1V 4AD, England

Facsimile No./Email: [***]

Attention: Director of Business Management

			
		  		  	 The University of Manchester

Oxford Road
 Manchester
M13 9PL, England
 Facsimile No./Email: [***] Attention: Director of Research &

Business Engagement Support Services

			
		  	 For Ideaya:
	  	 Ideaya Biosciences, Inc.

280 Utah Avenue, Suite 250

South San Francisco CA 94080

U.S.
 Email: [***]

Attention: CEO

		
		  	 with a copy to (which will not constitute notice):

			
		  		  	 Latham & Watkins LLP

140 Scott Drive
 Menlo
Park, California 94025
 Facsimile No.: [***]

Attention: [***]

  
 29 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. 

Confidential treatment has been requested with respect to the omitted portions. 

 13.8 Maintenance of Records Required by Law or Regulation. Each Party shall
keep and maintain all records required by Applicable Law with respect to Licensed Products and shall make copies of such records available to the other Party upon request. 

13.9 Assignment. No Party may assign or transfer this Agreement without the prior written consent of the other Parties (such
consent not to be unreasonably withheld, delayed or conditioned), except a Party may make such an assignment without the other Party’s consent to an Affiliate or to a Third Party successor (other than a Tobacco Party) to all or substantially
all of the business of such Party to which this Agreement relates, whether in a merger, sale of stock, sale of assets or other transaction. Any permitted assignment will be binding on the successors of the assigning Party. 

13.10 Further Actions. Each Party shall execute, acknowledge and deliver such further instruments, and to do all such other
acts, as may be necessary or reasonably appropriate to carry out the purposes and intent of this Agreement. 
 13.11
Severability. If any of the provisions of this Agreement are held to be invalid or unenforceable, the provision will be considered severed from this Agreement and will not serve to invalidate any remaining provisions hereof. The Parties shall
make a good faith effort to replace any invalid or unenforceable provision with a valid and enforceable provision such that the objectives contemplated by the Parties when entering this Agreement will be realized. 

13.12 Amendments; Waiver. No amendments or waivers of the terms and conditions of this Agreement will be binding upon either
Party unless in writing, signed by the Parties and specifying the provision of this Agreement that is amended or waived. No waiver by either Party of any breach of this Agreement by the other Party will be effective as to any other breach, whether
of the same or any other term or condition and whether occurring before or after the date of such waiver. 
 13.13 Construction of
this Agreement. Except where the context otherwise requires, wherever used, the use of any gender will be applicable to all genders, and the word “or” is used in the inclusive sense. When used in this Agreement,
“including” means “including without limitation”. References to either Party include the successors and permitted assigns of that Party. The headings of this Agreement are for convenience of reference only and in no
way define, describe, extend or limit the scope or intent of this Agreement or the intent of any provision contained in this Agreement. The Recitals and the Exhibits are incorporated by reference into this Agreement. The Parties have each consulted
counsel of their choice regarding this Agreement, and, accordingly, no provisions of this Agreement will be construed against either Party on the basis that the Party drafted this Agreement or any provision thereof. If the terms of this Agreement
conflict with the terms of any Exhibit, then the terms of this Agreement will govern. The official text of this Agreement and any Exhibits hereto, any notice given or accounts or statements required by this Agreement, and any dispute proceeding
related to or arising hereunder, will be in English. If any dispute arises concerning the construction or meaning of this Agreement, then reference will be made to this Agreement solely as written in English and not to any translation into any other
language. References to a Sublicensee and sublicensing shall be deemed to include Sublicensees and sublicensing at all tiers unless expressly stated otherwise. 

13.14 Counterparts. This Agreement may be executed in two (2) or more counterparts, each of which will be an original and
all of which will constitute together the same document. Counterparts may be signed and delivered by facsimile, or electronically in PDF, each of which will be binding when sent 

  
 30 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. 

Confidential treatment has been requested with respect to the omitted portions. 

 13.15 Joint & Several Liability. Any liability of the
Institute under this Agreement shall be several, and, as between CRT and Manchester, neither CRT nor Manchester shall have any liability for any breach or act or omission of the other Party under or in relation to this Agreement or its subject
matter. 
 Signature page follows. 

  
 31 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. 

Confidential treatment has been requested with respect to the omitted portions. 

 IN WITNESS WHEREOF, the
Parties have signed this Agreement by their authorized representatives as of the date below. The Parties acknowledge that the signature date may not be the Effective Date. 
  

									
	CANCER RESEARCH TECHNOLOGY LTD.	 		 	IDEAYA BIOSCIENCES, INC.

									
					
	By: 	 	/s/ [***]	 		 	By: 	 	/s/ [***]

									
	Title: Director, Business Management	 		 	Title:	 	[***]
	Date: April 28, 2017	 		 	Date:	 	April 28, 2017

  

			
	THE UNIVERSITY OF MANCHESTER
		
	By: 	 	/s/ [***]

			
	 Title:  Director of Research and Business Engagement Support
Services

	Date: 28/4/17

  
 32 

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. 

Confidential treatment has been requested with respect to the omitted portions. 

 Exhibit A 

Institute Background IP 
 [***] 

  
 [***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. 
 Confidential treatment has been
requested with respect to the omitted portions. 

 Exhibit B 

Research Plan 
 Bringing to the
Collaboration 
 IDEAYA 
  

	 	•	 	 [***] 

Manchester DDU 
  

	 	•	 	 [***] 

Research Plan 
 [***] 

  
 [***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. 
 Confidential treatment has been
requested with respect to the omitted portions. 

 Exhibit C 

Ideaya Diligence Report 
 [***] 

  
 [***] Certain information
in this document has been omitted and filed separately with the Securities and Exchange Commission. 
 Confidential treatment has been
requested with respect to the omitted portions.EX-10.3

 Exhibit 10.3 

Execution Version 

IDEAYA BIOSCIENCES, INC. 

AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

January 31, 2018 

 TABLE OF CONTENTS 

 

									
	 	  	 	  	 	  	Page	 
			
	1.	  	Registration Rights	  	 	1	 
		  	1.1	  	Definitions	  	 	1	 
		  	1.2	  	Request for Registration	  	 	3	 
		  	1.3	  	Company Registration	  	 	4	 
		  	1.4	  	Obligations of the Company	  	 	5	 
		  	1.5	  	Furnish Information	  	 	7	 
		  	1.6	  	Expenses of Registration	  	 	7	 
		  	1.7	  	Delay of Registration	  	 	8	 
		  	1.8	  	Indemnification	  	 	8	 
		  	1.9	  	Reports Under Exchange Act	  	 	10	 
		  	1.10	  	Form S-3 Registration	  	 	11	 
		  	1.11	  	Assignment of Registration Rights	  	 	11	 
		  	1.12	  	Termination of Registration Rights	  	 	12	 
		  	1.13	  	Limitations on Subsequent Registration Rights	  	 	12	 
			
	2.	  	Market Stand-Off Agreement	  	 	12	 
			
	3.	  	Covenants of the Company	  	 	13	 
		  	3.1	  	Delivery of Financial Statements	  	 	13	 
		  	3.2	  	Inspection	  	 	14	 
		  	3.3	  	Right of First Offer	  	 	14	 
		  	3.4	  	Confidential Information and Invention Assignment Agreements	  	 	15	 
		  	3.5	  	Indemnification	  	 	15	 
		  	3.6	  	Directors’ & Officers’ Liability	  	 	15	 
		  	3.7	  	Board Matters	  	 	16	 
		  	3.8	  	Stock Vesting	  	 	16	 
		  	3.9	  	Observer Rights	  	 	16	 
		  	3.10	  	Confidentiality	  	 	17	 
		  	3.11	  	Subsidiaries	  	 	18	 
		  	3.12	  	Indemnification Matters	  	 	18	 
		  	3.13	  	Termination of Covenants	  	 	18	 
			
	4.	  	Restrictions on Transferability of Securities; Compliance with Securities Act	  	 	19	 
		  	4.1	  	Restrictions on Transferability	  	 	19	 
		  	4.2	  	Notice of Proposed Transfers	  	 	19	 
			
	5.	  	Miscellaneous	  	 	20	 
		  	5.1	  	Successors and Assigns	  	 	20	 
		  	5.2	  	Governing Law	  	 	20	 
		  	5.3	  	Venue	  	 	20	 
		  	5.4	  	Counterparts	  	 	20	 
		  	5.5	  	Titles and Subtitles	  	 	20	 
		  	5.6	  	Notices	  	 	20	 
		  	5.7	  	Amendments and Waivers; Termination	  	 	21	 

  
 i 

									
		  	5.8	  	Severability	  	 	21	 
		  	5.9	  	Right to Invest	  	 	21	 
		  	5.10	  	Additional Parties	  	 	22	 
		  	5.11	  	Delays or Omissions	  	 	22	 
		  	5.12	  	Aggregation of Stock	  	 	22	 
		  	5.13	  	Electronic and Facsimile Signatures	  	 	22	 
		  	5.14	  	Entire Agreement	  	 	22	 
		  	5.15	  	Advice of Counsel	  	 	22	 

									
			
	Schedule A	  	Schedule of Investors	  			

  

  
 ii 

 Execution Version 

AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

This AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”) is made as of January 31, 2018, by
and among Ideaya Biosciences, Inc., a Delaware corporation (the “Company”) and the persons and entities listed on Schedule A hereto (each, an “Investor” and collectively, the “Investors”).

 WHEREAS, the Company and certain of the Investors (the “Existing Investors”) are parties to that certain
Investors’ Rights Agreement, dated March 1, 2016 (the “Prior Agreement”). 
 WHEREAS, pursuant to
Section 5.7 of the Prior Agreement and subject to certain specified exceptions, any term of the Prior Agreement may be amended and the observance of any term of the Prior Agreement may be waived (either generally or in a particular instance,
and either retroactively or prospectively) with the written consent of the Company and the holders of at least 60% of the Registrable Securities (as defined in the Prior Agreement) then-outstanding (the “Requisite Existing
Investors”). 
 WHEREAS, the Company and certain of the Investors (the “Participating Investors”) are
parties to that certain Series B Preferred Stock Purchase Agreement of even date herewith (as may be amended from time to time, the “Purchase Agreement”). 

WHEREAS, in order to induce the Company to enter into the Purchase Agreement and to induce the Participating Investors to invest funds
in the Company pursuant to the Purchase Agreement, the Company and the undersigned Existing Investors, constituting the Requisite Existing Investors, desire to amend and restate and supersede the Prior Agreement in its entirety as set forth herein
and to accept the rights created pursuant to this Agreement in lieu of the rights granted to them under the Prior Agreement. 
 NOW,
THEREFORE, the parties hereto hereby agree as follows: 
 1. Registration Rights. The Company covenants and agrees as follows:

 1.1 Definitions. For purposes of this Agreement: 

(a) “Acquisition” means a Liquidation (as defined in the Restated Certificate). 

(b) “Affiliate” as used in this Agreement shall have the meaning ascribed to such term in Rule 12b-2 of the General Rules and Regulations under the Exchange Act (as defined below). 
 (c)
“Board” means the Board of Directors of the Company. 
 (d) “Common Stock” means shares of the
Company’s common stock, par value $0.0001 per share. 

 (e) “Convertible Securities” means any bonds, debentures, notes or other
evidences of indebtedness, and any options, warrants, shares (including, but not limited to, shares of Preferred Stock) purchase rights or any other securities convertible into, exercisable for, or exchangeable for Common Stock. 

(f) “Exchange Act” means the Securities Exchange Act of 1934, as amended, or any similar successor federal statute, and the
rules and regulations thereunder, all as the same shall be in effect from time to time. 
 (g) “Form
S-3” means such form under the Securities Act as in effect on the date hereof or any registration form under the Securities Act subsequently adopted by the SEC (as defined below) that permits
inclusion or incorporation of substantial information by reference to other documents filed by the Company with the SEC. 
 (h)
“Holder” means any person owning or having the right to acquire Registrable Securities or any assignee thereof in accordance with Section 1.11 of this Agreement. 

(i) “Initiating Holders” means any Holder or Holders who in the aggregate hold at least 65% of the Registrable Securities
then-outstanding. 
 (j) “IPO” means an initial public offering of the Common Stock of the Company to the general public
that is effected pursuant to a registration statement filed with, and declared effective by, the SEC under the Securities Act in connection with which all outstanding shares of Preferred Stock will be converted to Common Stock. 

(k) “Preferred Stock” means the Series A Preferred Stock and the Series B Preferred Stock. 

(l) The terms “register,” “registered” and “registration” refer to a registration effected
by preparing and filing a registration statement or similar document in compliance with the Securities Act, and the declaration or ordering of effectiveness of such registration statement or document. 

(m) “Registrable Securities” means (i) the Common Stock issuable or issued upon conversion of the Preferred Stock and
(ii) any Common Stock of the Company issued as (or issuable upon conversion or exercise of any warrant, right or other security which is issued as) a dividend or other distribution with respect to or in exchange for or in replacement of the
shares referenced in clause (i) above; provided, however, that shares of Common Stock or other securities shall only be treated as Registrable Securities if and so long as they (A) have not been sold to or through a broker or dealer
or underwriter in a public distribution or a public securities transaction, (B) have not been transferred in a transaction pursuant to which the registration rights are not also assigned in accordance with Section 1.11
hereof or (C) with respect to each Holder, all such shares or other securities held by such Holder have become eligible for sale under Rule 144 (as defined below) (or any similar or successor rule) during any single ninety (90) day period.

  
 2 

 (n) The number of shares of “Registrable Securities then-outstanding”
shall be the sum of the number of shares of Common Stock outstanding that are, and the number of shares of Common Stock issuable pursuant to then outstanding Convertible Securities that are, Registrable Securities. 

(o) “Restated Certificate” means the Company’s Amended and Restated Certificate of Incorporation, as filed with the
Secretary of State of Delaware on or about the date hereof, as amended from time to time. 
 (p) “Restricted Securities”
means the securities of the Company required to bear the legends set forth in Section 3.6 of that certain Series A Preferred Stock Purchase Agreement, dated as of March 1, 2016, or Section 3.6 of the Purchase Agreement. 

(q) “Rule 144” means Rule 144 as promulgated by the SEC under the Securities Act, as such Rule may be amended from time to
time, or any similar successor rule that may be promulgated by the SEC. 
 (r) “SEC” shall mean the Securities and
Exchange Commission. 
 (s) “Securities Act” means the Securities Act of 1933, as amended, or any similar successor
federal statute, and the rules and regulations thereunder, all as the same shall be in effect from time to time. 
 (t) “Series A
Preferred Stock” means the Series A Preferred Stock of the Company, par value $0.0001 per share. 
 (u) “Series B
Preferred Stock” means the Series B Preferred Stock of the Company, par value $0.0001 per share. 
 1.2 Request for
Registration. 
 (a) Subject to the conditions of this Section 1.2, if the Company shall receive at any time
after the earlier of (i) January 31, 2023 or (ii) six months following the IPO, a written request from the Initiating Holders that the Company file a registration statement under the Securities Act covering the registration of
Registrable Securities which would have an aggregate offering price of not less than $10,000,000, then the Company shall within twenty (20) days of the receipt thereof, give written notice of such request to all Holders, and subject to the
limitations of this Section 1.2, use commercially reasonable efforts to effect, as soon as practicable, the registration under the Securities Act of all Registrable Securities that the Holders request to be registered in a
written request received by the Company within twenty (20) days of the mailing of the Company’s notice pursuant to this Section 1.2(a). 

(b) If the Initiating Holders intend to distribute the Registrable Securities covered by their request by means of an underwriting, they
shall so advise the Company as a part of their request made pursuant to Section 1.2(a) and the Company shall include such information in the written notice referred to in Section 1.2(a). The
underwriter will be selected by the Initiating Holders and shall be reasonably acceptable to the Company. In such event, the right of any Holder to include its Registrable Securities in such registration shall be conditioned upon such Holder’s
participation in such underwriting and the inclusion of such Holder’s Registrable Securities in the underwriting to the extent provided herein. All Holders proposing to distribute 

  
 3 

 
their securities through such underwriting shall enter into an underwriting agreement in customary form with the underwriter or underwriters selected for such underwriting. Notwithstanding any
other provision of this Section 1.2, if the underwriter advises the Initiating Holders in writing that marketing factors require a limitation of the number of shares to be underwritten, then the Company shall so advise all Holders of
Registrable Securities which would otherwise be underwritten pursuant hereto, and the number of shares of Registrable Securities that may be included in the underwriting shall be allocated, first, to the Initiating Holders and each Investor that
participated in the underwriting as a Holder on a pro rata basis based on the total number of Registrable Securities held by the Initiating Holders and participating Investors; and second, to the other Holders on a pro rata basis among
all such other Holders. 
 (c) Notwithstanding the foregoing, if the Company shall furnish to the Holders requesting a registration
statement pursuant to this Section 1.2 a certificate signed by the President and/or Chief Executive Officer of the Company stating that, in the good faith judgment of the Board, it would be materially detrimental to the
Company and its stockholders for such registration statement to be filed and it is therefore essential to defer the filing of such registration statement, the Company shall have the right to defer taking action with respect to such filing for a
period of not more than ninety (90) days after receipt of the request of the Initiating Holders; provided, however, that the Company may not utilize this right more than once in any twelve (12) month period. 

(d) In addition, the Company shall not be obligated to effect, or to take any action to effect, any registration pursuant to this
Section 1.2: 
 (i) after the Company has effected two (2) registrations pursuant to this
Section 1.2 and such registrations have been declared or ordered effective; 
 (ii) during the six-month period following the effective date of the registration statement pertaining to an IPO; 

(iii) if, within thirty (30) days of a registration request by the Initiating Holders, the Company gives notice to the Holders of its
intent to file or confidentially submit a registration statement for an IPO within ninety (90) days; or 
 (iv) if the Initiating
Holders propose to dispose of shares of Registrable Securities that may be immediately registered on Form S-3 pursuant to a request made pursuant to Section 1.10 below. 

1.3 Company Registration. 

(a) If (but without any obligation to do so) the Company proposes to register (including for this purpose a registration effected by the
Company for stockholders other than the Holders) any of its stock or other securities under the Securities Act in connection with the public offering of such securities solely for cash (other than a registration relating solely to the sale of
securities to participants in a Company stock plan, registration on any form which does not include substantially the same information as would be required to be included in a registration statement covering the sale of the Registrable Securities or
a registration in which the only Common Stock being registered is Common Stock issuable upon conversion of debt securities 

  
 4 

 
which are also being registered), the Company shall, at such time, promptly give each Holder written notice of such registration. Upon the written request of each Holder given within twenty
(20) days after mailing of such notice by the Company in accordance with Section 5.6, the Company shall, subject to the provisions of Section 1.3(b), cause to be registered under the Securities Act all of
the Registrable Securities that each such Holder has requested to be registered. Registrations effected pursuant to this Section 1.3 shall not be counted as demands for registration pursuant to
Section 1.2. 
 (b) If the registration statement under which the Company gives notice under this
Section 1.3 is for an underwritten offering, the Company shall so advise the Holders of Registrable Securities. In such event, the right of any such Holder to be included in a registration pursuant to this
Section 1.3 shall be conditioned upon such Holder’s participation in such underwriting and the inclusion of such Holder’s Registrable Securities in the underwriting to the extent provided herein. All Holders
proposing to distribute their Registrable Securities through such underwriting shall enter into an underwriting agreement in customary form with the underwriter or underwriters selected for such underwriting by the Company. Notwithstanding any other
provision of the Agreement, if the underwriter determines in good faith that marketing factors require a limitation of the number of shares to be underwritten, the number of shares that may be included in the underwriting shall be allocated, first,
to the Company; second, to the Holders on a pro rata basis based on the total number of Registrable Securities held by the Holders; and third, to any stockholder of the Company (other than a Holder) on a pro rata basis. No such
reduction shall reduce the amount of securities of the selling Holders included in the registration below thirty percent (30%) of the total amount of securities included in such registration, unless such offering is the IPO and such registration
does not include shares of any other selling stockholders, in which event any or all of the Registrable Securities of the Holders may be excluded in accordance with the immediately preceding sentence. For any Holder that is a partnership or
corporation, the partners, retired partners and shareholders of such Holder, or the estates and lineal descendants of any such partners and retired partners and any trusts for the benefit of any of the foregoing persons shall be deemed to be a
single “Holder,” and any pro rata reduction with respect to such “Holder” shall be based upon the aggregate amount of shares carrying registration rights owned by all entities and individuals included in such
“Holder,” as defined in this sentence. 
 (c) The Company shall have the right to terminate or withdraw any registration
initiated by it under this Section 1.3 prior to the effectiveness of such registration whether or not any Holder has elected to include securities in such registration. 

1.4 Obligations of the Company. Whenever required under this Section 1 to effect the registration of any
Registrable Securities, the Company shall, as expeditiously as reasonably possible: 
 (a) Prepare and file with the SEC a registration
statement with respect to such Registrable Securities and use reasonable efforts to cause such registration statement to become effective, and, upon the request of the Holders of 65% of the Registrable Securities registered thereunder, keep such
registration statement effective for a period of up to 120 days or, if earlier, until the distribution contemplated in the registration statement has been completed; provided, however, that 120 day period shall be extended for a period
of time equal to the period the Holders refrain, at the request of an underwriter of Common Stock (or other securities) of the Company, from selling any securities included in such registration. 

  
 5 

 (b) Prepare and file with the SEC such amendments and supplements to such registration
statement and the prospectus used in connection with such registration statement as may be necessary to comply with the provisions of the Securities Act with respect to the disposition of all securities covered by such registration statement. 

(c) Furnish to the Holders such numbers of copies of a prospectus, including a preliminary prospectus, in conformity with the requirements of
the Securities Act, and such other documents as they may reasonably request in order to facilitate the disposition of Registrable Securities owned by them. 

(d) Use reasonable efforts to register and qualify the securities covered by such registration statement under such other securities or blue
sky laws of such jurisdictions as shall be reasonably requested by the Holders; provided that the Company shall not be required in connection therewith or as a condition thereto to qualify to do business or to file a general consent to
service of process, or subject itself to general taxation, in any such states or jurisdictions. 
 (e) In the event of any underwritten
public offering, enter into and perform its obligations under an underwriting agreement, in usual and customary form, with the managing underwriter of such offering. Each Holder participating in such underwriting shall also enter into and perform
its obligations under such an agreement. 
 (f) Notify each Holder of Registrable Securities covered by such registration statement at any
time when a prospectus relating thereto is required to be delivered under the Securities Act or the happening of any event as a result of which the prospectus included in such registration statement, as then in effect, includes an untrue statement
of a material fact or omits to state a material fact required to be stated therein or necessary to make the statements therein not misleading in the light of the circumstances then existing. 

(g) Cause all such Registrable Securities registered pursuant hereunder to be listed on each securities exchange or nationally recognized
quotation system on which similar securities issued by the Company are then listed. 
 (h) Provide a transfer agent and registrar for all
Registrable Securities registered pursuant hereunder and a CUSIP number for all such Registrable Securities, in each case not later than the effective date of such registration. 

(i) Reasonably cooperate in all necessary respects with (A) counsel in preparation of the customary legal opinions and
(B) accountants in preparation of the customary comfort letters, copies of which shall be provided to each Holder so requesting; provided that the Holders shall not be entitled to rely upon such legal opinions and comfort letters other
than in accordance with their own respective terms. 

  
 6 

 (j) Make available for inspection by the selling Holders, any underwriter(s) participating
in any disposition pursuant to such registration statement, and any attorney or accountant or other agent retained by any such underwriter or selected by the selling Holders, all financial and other records, pertinent corporate documents, and
properties of the Company, and cause the Company’s officers, directors, employees, and independent accountants to supply all information reasonably requested by any such seller, underwriter, attorney, accountant, or agent, in each case, as
necessary or advisable to verify the accuracy of the information in such registration statement and to conduct appropriate due diligence in connection therewith, provided that any information obtained pursuant to this subsection (j) shall be
subject to the confidentiality and non-use obligations of Section 3.10 of this Agreement, and the selling Holders shall be responsible for any breach thereof by any underwriter or other agent of such
selling Holder. 
 (k) After such registration statement becomes effective, notify each selling Holder of any request by the SEC that the
Company amend or supplement such registration statement or prospectus. 
 1.5 Furnish Information. 

(a) It shall be a condition precedent to the obligations of the Company to take any action pursuant to this
Section 1 with respect to the Registrable Securities of any selling Holder that such Holder shall furnish to the Company such information regarding itself, the Registrable Securities held by it, and the intended method of
disposition of such securities as shall be required to effect the registration of such Holder’s Registrable Securities. 
 (b) The
Company shall have no obligation with respect to any registration requested pursuant to Section 1.10 if, due to the operation of Section 1.5(a), the number of shares of the Registrable Securities
to be included in the registration does not equal or exceed the number of shares required to originally trigger the Company’s obligation to initiate such registration as specified in Section 1.10(b). 

1.6 Expenses of Registration. All expenses (other than underwriting discounts and commissions, stock transfer taxes and fees of counsel
to the selling shareholders (except as set forth below)) incurred in connection with registrations, filings or qualifications pursuant to Section 1.2, Section 1.3 and Section 1.10, including
(without limitation) all registration, filing and qualification fees, printers’ and accounting fees, fees and disbursements of counsel for the Company and the reasonable fees and disbursements of one counsel for the selling Holders (not to
exceed $35,000), shall be borne by the Company; provided, however, that the Company shall not be required to pay for any expenses of any registration proceeding begun pursuant to Section 1.2(a) or
Section 1.10 if the registration request is subsequently withdrawn at the request of the Holders of at least 65% of the Registrable Securities to be registered (in which case all participating Holders shall bear such
expenses pro rata based upon the number of Registrable Securities that were to be registered in the withdrawn registration) unless such Holders agree to forfeit their right to one registration pursuant to
Section 1.2(a) or Section 1.10, as the case may be; provided, however, that if at the time of such withdrawal, the Holders (i) have learned of a material adverse change in the
condition, business, or prospects of the Company that was not known at the time of their requestor could have not been reasonably known given the prior communication or information provided by the Company to the Holders and (ii) have withdrawn
the request with reasonable promptness following disclosure by the Company of such material adverse change, then the Holders shall not be required to pay any of such expenses and shall not forfeit their right to one registration pursuant to
Section 1.2(a) or Section 1.10. 

  
 7 

 1.7 Delay of Registration. No Holder shall have any right to obtain or seek an
injunction restraining or otherwise delaying any such registration as the result of any controversy that might arise with respect to the interpretation or implementation of this Section 1. 

1.8 Indemnification. In the event any Registrable Securities are included in a registration statement under this
Section 1: 
 (a) To the extent permitted by law, the Company will indemnify and hold harmless each Holder, any
underwriter (as defined in the Securities Act) for such Holder and each person, if any, who controls such Holder or underwriter within the meaning of the Securities Act or the Exchange Act, against any losses, claims, damages or liabilities (joint
or several) to which they may become subject under the Securities Act, the Exchange Act or other federal or state law, insofar as such losses, claims, damages or liabilities (or actions in respect thereof) arise out of or are based upon any of the
following statements, omissions or violations (collectively, a “Violation”): (i) any untrue statement or alleged untrue statement of a material fact contained in such registration statement, including any preliminary prospectus or
final prospectus contained therein or any amendments or supplements thereto, (ii) the omission or alleged omission to state therein a material fact required to be stated therein, or necessary to make the statements therein not misleading or
(iii) any violation or alleged violation by the Company of the Securities Act, the Exchange Act, any state securities law or any rule or regulation promulgated under the Securities Act, the Exchange Act or any state securities law; and the
Company will pay to each such Holder, underwriter or controlling person any legal or other expenses reasonably incurred, as incurred, by them in connection with investigating or defending any such loss, claim, damage, liability or action;
provided, however, that the indemnity agreement contained in this Section 1.8(a) shall not apply to amounts paid in settlement of any such loss, claim, damage, liability or action if such settlement is effected
without the consent of the Company (which consent shall not be unreasonably withheld, conditioned or delayed), nor shall the Company be liable in any such case for any such loss, claim, damage, liability or action to the extent that it arises out of
or is based upon a Violation which occurs in reliance upon and in conformity with written information furnished expressly for inclusion in a registration statement in connection with such registration by such Holder, underwriter or controlling
person and; provided further, however, that the foregoing indemnity agreement with respect to any preliminary prospectus shall not inure to the benefit of any Holder or underwriter, or any person controlling such Holder or underwriter, from
whom the person asserting any such losses, claims, damages or liabilities purchased shares in the offering, if a copy of the prospectus (as then amended or supplemented) was not sent or given by or on behalf of such Holder or underwriter to such
person, if required by law so to have been delivered by such Holder, at or prior to the written confirmation of the sale of the shares to such person, and if the prospectus (as so amended or supplemented) would have cured the defect giving rise to
such loss, claim, damage or liability. 
 (b) To the extent permitted by law, each Holder selling Registrable Securities in a registration
under this Agreement, severally and not jointly, will indemnify and hold harmless the Company, each of its directors, each of its officers who has signed the registration statement, each person, if any, who controls the Company within the meaning of
the 

  
 8 

 
Securities Act, legal counsel and accountants for the Company, any underwriter, any other Holder selling securities in such registration statement and any controlling person of any such
underwriter or other Holder, against any losses, claims, damages or liabilities (joint or several) to which any of the foregoing persons may become subject, under the Securities Act, the Exchange Act or other federal or state law, insofar as such
losses, claims, damages or liabilities (or actions in respect thereto) arise out of or are based upon any Violation, in each case to the extent (and only to the extent) that such Violation occurs in reliance upon and in conformity with written
information furnished by such Holder expressly for use in connection with such registration; and each such Holder will pay any legal or other expenses reasonably incurred, as incurred, by any person intended to be indemnified pursuant to this
Section 1.8(b), in connection with investigating or defending any such loss, claim, damage, liability or action; provided, however, that the indemnity agreement contained in this
Section 1.8(b) shall not apply to amounts paid in settlement of any such loss, claim, damage, liability or action if such settlement is effected without the consent of the Holder, which consent shall not be unreasonably
withheld, conditioned or delayed, provided that in no event shall any indemnity under this Section 1.8(b) plus any contribution under this Section 1.8 exceed the net proceeds from the
offering received by such Holder. 
 (c) Promptly after receipt by an indemnified party under this Section 1.8 of
notice of the commencement of any action (including any governmental action), such indemnified party will, if a claim in respect thereof is to be made against any indemnifying party under this Section 1.8, deliver to the
indemnifying party a written notice of the commencement thereof and the indemnifying party shall have the right to participate in, and, to the extent the indemnifying party so desires, jointly with any other indemnifying party similarly noticed, to
assume the defense thereof with counsel mutually satisfactory to the parties; provided, however, that prior to assuming control of such defense, the indemnifying party must acknowledge that, if the facts as alleged by the claimant in such
claim are true, it would have an indemnity obligation for the expenses, losses, claims, damages and liabilities resulting from such claim as provided hereunder and must furnish the indemnified party with reasonable evidence that the indemnifying
party has adequate resources to defend such claim and fulfill its indemnity obligations hereunder; and the indemnifying party shall not be entitled to assume or maintain control of the defense of any claim and shall pay the fees and expenses of one
counsel retained by the indemnified party if (i) the indemnifying party does not deliver the acknowledgment referred to above within thirty (30) days of receipt of notice of the claim, (ii) the claim relates to or arises in connection
with any criminal proceeding, action, indictment or allegation, (iii) the indemnified party reasonably believes an adverse determination with respect to the claim would be detrimental to the reputation or future business prospects of the
indemnified party or any of its affiliates, (iv) the claim seeks an injunction or equitable relief against the indemnified party or any of its affiliates or (v) the indemnifying party has failed or is failing to prosecute or defend
vigorously the claim; provided, further, however, that an indemnified party (together with all other indemnified parties which may be represented without conflict by one counsel) shall have the right to retain one separate counsel, with the
fees and expenses to be paid by the indemnifying party, if representation of such indemnified party by the counsel retained by the indemnifying party would be inappropriate due to actual or potential differing interests between such indemnified
party and any other party represented by such counsel in such proceeding. The failure of any indemnified party to give notice as provided herein shall not relieve the indemnifying party of its obligations under this Agreement, except to the extent
that the indemnifying party’s ability to defend against such claim or litigation is materially impaired as a result of such failure to give notice. No indemnifying 

  
 9 

 
party in the defense of any such claim or litigation shall, except with the consent of each indemnified party, consent to entry of any judgment or enter into any settlement that does not include
as an unconditional term thereof the giving by the claimant or plaintiff to such indemnified party of a release from all liability in respect of such claim or litigation (which consent shall not be unreasonably withheld, conditioned or delayed), and
no indemnified party shall consent to entry of any judgment or settle such claim or litigation without the prior written consent of the indemnifying party (which consent shall not be unreasonably withheld, conditioned or delayed). 

(d) If the indemnification provided for in this Section 1.8 is held by a court of competent jurisdiction to be
unavailable to an indemnified party with respect to any loss, liability, claim, damage or expense referred to therein, then the indemnifying party, in lieu of indemnifying such indemnified party hereunder, shall contribute to the amount paid or
payable by such indemnified party as a result of such loss, liability, claim, damage or expense in such proportion as is appropriate to reflect the relative fault of the indemnifying party on the one hand and of the indemnified party on the other in
connection with the statements or omissions that resulted in such loss, liability, claim, damage or expense as well as any other relevant equitable considerations; provided that in no event shall any contribution under this
Section 1.8(d) when combined with any payment made pursuant to Section 1.8(b) hereunder by a Holder exceed the net proceeds from the offering received by such Holder. The relative fault of the
indemnifying party and of the indemnified party shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission to state a material fact relates to information supplied by
the indemnifying party or by the indemnified party and the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission. 

(e) Unless otherwise superseded by an underwriting agreement entered into in connection with the underwritten public offering, the
obligations of the Company and Holders under this Section 1.8 shall survive the completion of any offering of Registrable Securities in a registration statement under this Section 1 and otherwise
shall survive the termination of this Agreement. 
 1.9 Reports Under Exchange Act. With a view to making available to the Holders
the benefits of Rule 144 and any other rule or regulation of the SEC that may at any time permit a Holder to sell securities of the Company to the public without registration or pursuant to a registration on Form
S-3, the Company agrees to: 
 (a) make and keep public information available, as those terms are
understood and defined in Rule 144, at all times after ninety (90) days after the effective date of the IPO; 
 (b) file with the SEC
in a timely manner all reports and other documents required of the Company under the Securities Act and the Exchange Act (at any time after the Company has become subject to such reporting requirements); and 

  
 10 

 (c) furnish to any Holder, so long as the Holder owns any Registrable Securities, forthwith
upon request (i) a written statement by the Company that it has complied with the reporting requirements of Rule 144 (at any time after ninety (90) days after the effective date of the first registration statement filed by the Company),
the Securities Act and the Exchange Act (at any time after it has become subject to such reporting requirements), or that it qualifies as a registrant whose securities may be resold pursuant to Form S-3 (at
any time after it so qualifies), (ii) a copy of the most recent annual or quarterly report of the Company and such other reports and documents so filed by the Company and (iii) such other information as may be reasonably requested in availing
any Holder of any rule or regulation of the SEC which permits the selling of any such securities without registration or pursuant to such form. 

1.10 Form S-3 Registration. In case the Company shall receive from the Initiating Holders, a
written request or requests that the Company effect a registration on Form S-3 and any related qualification or compliance with respect to all or a part of the Registrable Securities owned by such Initiating
Holder or Holders, the Company will: 
 (a) promptly give written notice of the proposed registration, and any related qualification or
compliance, to all other Holders; and 
 (b) use reasonable efforts to effect such registration and all such qualifications and compliances
as may be so requested and as would permit or facilitate the sale and distribution of all or such portion of such Initiating Holder’s or Holders’ Registrable Securities as are specified in such request, together with all or such portion of
the Registrable Securities of any other Holder or Holders joining in such request as are specified in a written request given within fifteen (15) days after receipt of such written notice from the Company; provided, however, that the
Company shall not be obligated to effect any such registration, qualification or compliance, pursuant to this Section 1.10: (i) if Form S-3 is not available for such offering by the
Initiating Holders; (ii) if the Initiating Holders propose to sell Registrable Securities and such other securities (if any) at an aggregate price to the public (net of any underwriters’ discounts or commissions) of less than $5,000,000;
(iii) after the Company has effected two (2) registrations pursuant to this Section 1.10 in any twelve (12) month period and such registrations have been declared or ordered effective; (iv) if the Company
shall furnish to the Initiating Holders a certificate signed by the President and/or Chief Executive Officer of the Company stating that in the good faith judgment of the Board, it would be materially detrimental to the Company and its stockholders
for such Form S-3 registration to be filed at such time, in which event the Company shall have the right to defer the filing of the Form S-3 registration statement for a
period of not more than ninety (90) days after receipt of the request of the Holder or Holders under this Section 1.10; provided, however, that the Company shall not utilize this right more than once in any
twelve (12) month period; or (v) in any particular jurisdiction in which the Company would be required to qualify to do business or to execute a general consent to service of process in effecting such registration, qualification or
compliance or otherwise subject itself to general taxation. Subject to the foregoing, the Company shall file a registration statement covering the Registrable Securities and other securities so requested to be registered as soon as practicable after
receipt of the request or requests of the Holders. Registrations effected pursuant to this Section 1.10 shall not be counted as demands for registration effected pursuant to Section 1.2. 

1.11 Assignment of Registration Rights. The rights to cause the Company to register Registrable Securities pursuant to this
Section 1 may be assigned (but only with all related obligations) by (i) a Holder that is a partnership, to any subsidiary, parent, partner, retired partner or affiliated fund of such Holder, (ii) a Holder that is
a limited liability company, to any member 

  
 11 

 
or former member of such Holder, (iii) a Holder who is an individual, to such Holder’s family member or trust for the benefit of such Holder or such Holder’s family member,
(iv) a Major Investor (as defined in Section 3.3) to an Affiliate or (v) a Holder to any other person acquiring at least 1,000,000 shares of Registrable Securities (as appropriately adjusted for any stock split,
dividend, combination or other recapitalization or like transactions) (or all of such transferring Holder’s shares if less); provided (in all cases) that (a) the Company is, within a reasonable time after such transfer, furnished
with written notice of the name and address of such transferee or assignee and the securities with respect to which such registration rights are being assigned; (b) such transferee or assignee agrees in writing to be bound by and subject to the
terms and conditions of this Agreement, including without limitation the provisions of Section 2 below; and (c) such assignment shall be effective only if immediately following such transfer the further disposition of
such securities by the transferee or assignee is restricted under the Securities Act. 
 1.12 Termination of Registration Rights. No
Holder shall be entitled to exercise any right provided for in this Section 1 after the earliest to occur of the following: (i) the third anniversary of the effective date of the IPO, (ii) the date when all
Registrable Securities held by such Holder can be sold in any ninety (90) day period without registration in compliance with Rule 144 or (iii) upon the consummation of an Acquisition. 

1.13 Limitations on Subsequent Registration Rights. From and after the date of this Agreement, the Company shall not, without the prior
written consent of the Holders of at least 65% of the Registrable Securities then-outstanding, enter into any agreement with any holder or prospective holder of any securities of the Company which would allow such holder or prospective holder to
include such securities in any registration filed under Sections 1.2 or 1.3 hereof, unless under the terms of such agreement, such holder or prospective holder may include such securities in any such registration only to the extent
that the inclusion of his securities will not reduce the amount of the Registrable Securities of the Holders which is included. 
 2.
Market Stand-Off Agreement. Each Holder hereby agrees that in connection with an IPO, such Holder shall not sell, transfer, make any short sale of, grant any option for the purchase of, or enter into
any hedging or similar transaction with the same economic effect as a sale, any Common Stock (or other securities) of the Company held by such Holder (other than those included in the registration) for a period specified by the representative of the
underwriters of Common Stock (or other securities) of the Company not to exceed one hundred eighty (180) days following the effective date of a registration statement of the Company filed under the Securities Act in connection with the
Company’s IPO (the “Stand-Off Period”) as long as all stockholders individually owning more than one percent (1%) of the Company’s then outstanding shares of Common Stock (after
giving effect to conversion into Common Stock of all outstanding shares of Preferred Stock) and all executive officers and directors enter into similar agreements. Each Holder agrees to execute and deliver such other agreements as may be reasonably
requested by the Company or the underwriter which are consistent with the foregoing or which are necessary to give further effect thereto. The Company may impose stop-transfer instructions with respect to the shares of Common Stock (or other
securities) subject to the foregoing restriction until the end of said one hundred eighty (180) day period. The underwriters of the Company’s stock are intended third-party beneficiaries of this Section 2 and
shall have the right, power and authority to enforce the provisions hereof as though they were a party hereto. Any discretionary waiver or termination of the restrictions of any or all of such agreements by the Company or the underwriters shall
apply pro rata to all Holders subject to such agreements, based on the number of shares subject to such agreements. 

  
 12 

 3. Covenants of the Company. 

3.1 Delivery of Financial Statements. The Company shall deliver to each Major Investor (as defined in
Section 3.3): 
 (a) as soon as practicable, but in any event within one hundred twenty (120) days after the
end of each fiscal year of the Company (or such other time that the Board unanimously approves), an income statement for such fiscal year, a balance sheet of the Company and statement of stockholder’s equity as of the end of such fiscal year,
and a statement of cash flows for such fiscal year, such year-end financial reports to be in reasonable detail and prepared in accordance with generally accepted accounting principles
(“GAAP”), and audited and certified by an independent public accounting firm selected with the approval of the Board; 

(b) as soon as practicable, but in any event within one hundred twenty (120) days after the end of each fiscal year of the Company (or
such other time that the Board unanimously approves), a comparison of the Company’s audited financial statements and results of operations against the Company’s annual budget from such fiscal year, setting forth in reasonable detail the
variances between the actual results of operations and budgeted or forecasted results; 
 (c) as soon as practicable, but in any event
within forty five (45) days after the end of each quarter of each fiscal year of the Company, an unaudited income statement, an unaudited statement of cash flows for such fiscal quarter and an unaudited balance sheet for such quarter, such
quarterly financial reports to be in reasonable detail; 
 (d) as soon as practicable after the end of each calendar month, and in any
event within thirty (30) days thereafter, an unaudited income statement, an unaudited statement of cash flows for such month, and an unaudited balance sheet for such month, such monthly financial reports to be in reasonable detail; 

(e) as soon as practicable, but in any event at least thirty (30) days prior to the end of each fiscal year, a budget for the next
fiscal year, including balance sheets, income statements and statements of cash flows, such budget to be in reasonable detail and prepared on a monthly basis; and 

(f) as soon as practicable, but in any event within forty-five (45) days after the end of each quarter of each fiscal year of the
Company, a statement showing the number of shares of each class and series of capital stock and securities convertible into or exercisable for shares of capital stock outstanding at the end of such quarter, the Common Stock issuable upon conversion
or exercise of any outstanding securities convertible or exercisable for Common Stock and the exchange ratio or exercise price applicable thereto, and the number of shares of issued stock options and stock options not yet issued but reserved for
issuance, if any, all in sufficient detail as to permit the Major Investors to calculate their respective percentage equity ownership in the Company. 

  
 13 

 If, for any period, the Company has any subsidiary whose accounts are consolidated with
those of the Company, then in respect of such period the financial statements delivered pursuant to the foregoing sections shall be the consolidated and consolidating financial statements of the Company and all such consolidated subsidiaries. 

3.2 Inspection. The Company shall permit each Major Investor, at such Major Investor’s expense, to visit and inspect the
Company’s properties, to examine its books of account and records and to discuss the Company’s affairs, finances and accounts with its officers, all at such reasonable times as may be convenient to the Company and such Major Investor;
provided, however, that the Company shall not be obligated pursuant to this Section 3.2 to provide access to any information which it reasonably considers to be a trade secret or similar confidential information.

 3.3 Right of First Offer. 

(a) Subject to the terms and conditions specified in this Section 3.3, the Company hereby grants to each Investor,
for so long as an Investor holds at least 1,000,000 shares of Common Stock issued or issuable upon conversion of the Preferred Stock (as appropriately adjusted for any stock split, dividend, combination or other recapitalization or like transaction)
(such Investor, a “Major Investor”), the right of first offer with respect to future issuances by the Company of its Shares (as hereinafter defined). A Major Investor shall be entitled to apportion the right of first offer hereby
granted it among itself and its partners and Affiliates in such proportions as it deems appropriate. Each time following the date hereof that the Company proposes to offer or issue any shares of any class of its capital stock or any Convertible
Securities (“Shares”), the Company shall first make an offering of such Shares to each Major Investor in accordance with the following provisions. The Company shall deliver a notice in accordance with
Section 5.6 to the Major Investors stating (i) its bona fide intention to offer such Shares, (ii) the number of such Shares to be offered and (iii) the price and terms upon which it proposes to offer
such Shares. If any prospective purchaser has offered to pay for any Shares with property, services or any other non-cash consideration, then the Major Investors shall nevertheless have the right to pay for
such Shares with cash in an amount equal to the fair market value of the non-cash consideration offered by the prospective purchaser, where the fair market value of such
non-cash consideration shall be conclusively determined in good faith by the Board. 
 (b) By
written notification received by the Company, within twenty (20) calendar days after delivery of the notice, the Major Investor may elect to purchase, at the price and on the terms specified in the notice, up to that portion of such Shares that
equals the proportion that the number of shares of Common Stock issued and held, or issuable upon conversion of the Preferred Stock then held, by such Major Investor bears to the total number of shares of Common Stock of the Company then-outstanding
(assuming full conversion of all outstanding convertible securities). The Company shall promptly, in writing, inform each Major Investor that elects to purchase all the shares available to it (a “Fully-Exercising Investor”) of any
other Major Investor’s failure to do likewise. During the ten (10) day period commencing after such information is given, each Fully-Exercising Investor may elect to purchase that portion of the Shares for which Major Investor were
entitled to subscribe but which were not subscribed for that is equal to the proportion that the number of shares of Common Stock issued and held, or issuable upon conversion of Preferred Stock then held, by such Fully-Exercising Investor bears to
the total number of shares of Common Stock issued and held, or issuable upon conversion of the Preferred Stock then held, by all Fully-Exercising Investors who wish to purchase some of the unsubscribed shares. 

  
 14 

 (c) If all Shares that Major Investors are entitled to purchase pursuant to
Section 3.3(b) are not elected to be purchased as provided in Section 3.3(b) hereof, the Company may, during the ninety (90) day period following the expiration of the period provided in
Section 3.3(b) hereof, offer the remaining unsubscribed portion of such Shares to any person or persons at a price not less than, and upon terms no more favorable to the offeree than those specified in the notice. If the
Company does not enter into a definitive binding agreement for the sale of the Shares within such period, or if such agreement is not consummated within sixty (60) days of the execution thereof, the right provided hereunder shall be deemed to
be revived and such Shares shall not be offered unless first reoffered to the Major Investors in accordance herewith. 
 (d) The right of
first offer in this Section 3.3 shall not be applicable to the Exempted Securities (as defined in the Restated Certificate). 

(e) Notwithstanding the foregoing, the right of first offer in this Section 3.3 shall not be applicable to any
Major Investor with respect to any subsequent issuance of Shares if: (i) at the time of such subsequent issuance of Shares, such Major Investor is not an accredited investor as defined in Rule 501(a) of Regulation D promulgated under the
Securities Act and (ii) such subsequent issuance of Shares is otherwise being offered only to accredited investors as defined in Rule 501(a) of Regulation D promulgated under the Securities Act. 

3.4 Confidential Information and Invention Assignment Agreements. The Company shall require all employees to execute and deliver a
confidential information and invention assignment agreement substantially in a form approved by the Board. The Company shall require all directors, consultants and independent contractors to the Company that have had access to the Company’s
intellectual property to enter into an agreement containing appropriate confidentiality and invention assignment provisions. 
 3.5
Indemnification. The Company shall use its reasonable efforts to provide that its Restated Certificate and bylaws provide for indemnification of officers and directors of the Company to the maximum extent permitted by law. If the Company or
any of its successors or assignees consolidates with or merges into any other entity and is not the continuing or surviving corporation or entity of such consolidation or merger, then to the extent necessary, proper provision shall be made so that
the successors and assignees of the Company assume the obligations of the Company with respect to indemnification of members of the Board as in effect immediately before such transaction, whether such obligations are contained in the Company’s
Bylaws, its Certificate of Incorporation, or elsewhere, as the case may be. 
 3.6 Directors’ & Officers’ Liability.
The Company shall use commercially reasonable efforts to obtain from financially sound and reputable insurers, and thereafter maintain, a policy or policies of directors’ and officers’ liability insurance on terms and conditions
satisfactory to the Board, including a majority of then-serving Preferred Directors, and with a coverage limit of not less than $2,000,000, and will use commercially reasonable efforts to cause such policy to be maintained until such time as the
Board, including the approval of a majority of the then-serving Preferred Directors, determines that such insurance should be discontinued or otherwise modified. 

  
 15 

 3.7 Board Matters. Upon request, the Company shall promptly reimburse in full, each
Observer (as defined below) and non-employee director of the Company for his or her reasonable and documented out-of-pocket
expenses incurred in connection with the attendance of meetings of the Board or any committee thereof or in the course of pre-approved business conducted on behalf of the Company. 

3.8 Stock Vesting. Unless otherwise approved by the Board, including the approval of a majority of the then-serving Preferred
Directors, all stock, stock options and other stock equivalents issued after the date of this Agreement to employees shall be subject to vesting no earlier than as follows: (a) twenty-five percent (25%) of such stock shall vest at the end of
the first year following the earlier of the date of issuance or such person’s services commencement date with the Company and (b) seventy-five percent (75%) of such stock shall vest in equal monthly installments over the remaining three
(3) years. With respect to any shares of stock purchased by any such person still subject to vesting, the Company’s repurchase option shall provide that upon such person’s termination of employment or service with the Company, with or
without cause, the Company or its assignee shall have the option to purchase at cost any unvested shares of stock held by such person. No stock option, restricted stock and similar equity grant issued to officers and consultants shall be
transferable until such time as such stock option, restricted stock and similar equity grant is fully vested. No stock option shall have a maximum term of more than ten (10) years. 

3.9 Observer Rights. The Company covenants and agrees with each of 5AM Ventures (as defined below), Canaan X L.P., Celgene Corporation
(“Celgene”), Roche Finance Ltd (“Roche”) and BVF Partners LP (each, together with their respective Affiliates, an “Investor with Observer Rights”) that, for so long as such Investor with Observer
Rights is a Major Investor, such Investor with Observer Rights shall be entitled to designate one observer (each, an “Observer” and together, the “Observers”) to attend all meetings of the Board, including
telephonic meetings, and the Company will give each Observer notice of such meetings, by telecopy or by such other means as such notices are delivered to the members of the Board, not later than the same time notice is provided or delivered to the
Board; provided that the Observer agrees to hold in confidence all information regarding the Company provided to such Observer acting in such capacity; and provided further that the Observer may be excluded from any meeting or portion
thereof and the Company reserves the right to withhold any information from such Observer if the Company reasonably believes that such withholding of information or exclusion is reasonably necessary to preserve the attorney-client privilege, to
protect highly confidential proprietary information, if the Board determines in good faith that there exists, with respect to the subject of such deliberation or of such Board materials, an actual or potential conflict of interest between the
Observer or the Investor with Observer Rights that designated such Observer and the Company, or for other similar reasons. As used herein, “5AM Ventures” means 5AM Ventures IV, L.P. and 5AM
Co-Investors IV, L.P., collectively. 

  
 16 

 3.10 Confidentiality. Each Investor agrees, severally and not jointly, to use the
same degree of care as such Investor uses to protect its own confidential information for any information obtained pursuant to Section 3.1, Section 3.2 and Section 3.9
hereof and such Investor acknowledges that it will not, without the prior written consent of the Company, disclose, divulge or use for any purpose (other than to monitor its investment in the Company) such information without the prior written
consent of the Company except such information that (a) was in the public domain prior to the time it was furnished to such Investor, (b) is or becomes (through no breach of this Section 3.10 or any other
contractual obligation of confidentiality by such Investor) generally available to the public, (c) was in the possession of, or known by, such Investor prior to receipt from the Company without a breach of any obligation of confidentiality
known to such Investor to be owed to the Company, (d) was made known or disclosed to such Investor by a third party without a breach of any obligation of confidentiality such third party may have to the Company or (e) was independently
developed without any use of the Company’s confidential information. Notwithstanding the foregoing, (i) each Investor that is a limited partnership or limited liability company may disclose such information to (x) any former partners
or members who retained an economic interest in such Investor or (y) any current or prospective partner of the partnership or any subsequent partnership under common investment management, limited partner, general partner, member or management
company of such Investor (or any employee or representative of any of the foregoing); (ii) each Investor that is a corporation may disclose such proprietary or confidential information to any Affiliate (or any employee or representative of any of
the foregoing); (iii) each Investor may disclose such information to the legal counsel, accountants or representatives for such Investor; and (iv) each Investor may disclose such information to any prospective purchaser of any Registrable
Securities from such Investor if such prospective purchaser executed a customary confidentiality agreement, reasonably acceptable to the Company, with such Investor; provided, however, that, notwithstanding the foregoing, no Investor shall
disclose information pursuant to subsection (iv) of this Section 3.10 unless such Investor has provided the Company with written notice thereof (including the identity of the party to whom such Investor intends to
disclose such information and the executed confidentiality agreement to which such party is subject) at least five (5) business days prior to such disclosure; and provided further, however, that in no event shall any Investor disclose
information pursuant to subsection (iv) of this Section 3.10 to any competitor of the Company. In the event that the Investor is requested by any governmental authority or required by law to disclose any information of
the Company, the Investor shall, to the extent permitted by applicable law, promptly notify the Company in writing of such request or requirement and the scope and nature of disclosure so requested or required so that the Company, at its own
expense, may seek an appropriate protective order or other remedy to protect the confidentiality of the confidential information and/or take other lawful action to protect its interests, and the Investor, at the Company’s expense, will provide
reasonable assistance to the Company in connection therewith. In the absence of a protective order or the receipt of a written waiver from the Company’s chief executive officer hereunder with respect to any such disclosure, the Investor will
disclose only that portion of the Company’s information that is requested, or as the Investor is advised by legal counsel is required, to be disclosed. Neither the Company nor any of its affiliates shall use the name of Celgene, Roche or
Novartis Institutes for Biomedical Research, Inc. (“Novartis”) or the name of any of Celgene’s, Roche’s or Novartis’ affiliates in any press release, published notice or other publication relating to such
Investor’s investment in the Company without the prior written consent of such Investor. For the avoidance of doubt, the Company may advise its tax, legal or other professional advisors, other investors and prospective investors of the fact of
the investments by Celgene, Roche and Novartis in the Company, provided that such persons are obligated to keep such information confidential, and the Company may make any other disclosure regarding the investments of Celgene, Roche and Novartis in
the Company as required by law or legal process. 

  
 17 

 3.11 Subsidiaries. The Company will not, without the approval of the Board:
(a) organize or acquire any entity that is a subsidiary unless such subsidiary is wholly owned by the Company, (b) permit any subsidiary to consolidate or merge into or with any entity or sell or transfer all or substantially all its
assets, except that the Company may permit a subsidiary to consolidate or merge into or with or sell or transfer assets to any other subsidiary or (c) sell or otherwise transfer any shares of capital stock of any subsidiary or other equity
securities of any entity, except to the Company or another subsidiary, or permit any subsidiary to issue, sell or otherwise transfer any shares of its capital stock or the capital stock of any subsidiary or other equity securities of any entity or
to sell all or substantially all of such subsidiary’s assets, except to the Company or another subsidiary. 
 3.12 Indemnification
Matters. The Company hereby acknowledges that one (1) or more of the directors nominated to serve on the Board by the Investors (each a “Fund Director”) may have certain rights to indemnification, advancement of expenses
and/or insurance provided by one or more of the Investors and certain of their affiliates (collectively, the “Fund Indemnitors”). The Company hereby agrees (a) that it is the indemnitor of first resort (i.e., its
obligations to any such Fund Director are primary and any obligation of the Fund Indemnitors to advance expenses or to provide indemnification for the same expenses or liabilities incurred by such Fund Director are secondary), (b) that it shall be
required to advance the full amount of expenses incurred by such Fund Director and shall be liable for the full amount of all expenses, judgments, penalties, fines and amounts paid in settlement by or on behalf of any such Fund Director to the
extent legally permitted and as required by the Company’s Certificate of Incorporation or Bylaws of the Company (or any agreement between the Company and such Fund Director), without regard to any rights such Fund Director may have against the
Fund Indemnitors, and, (c) that it irrevocably waives, relinquishes and releases the Fund Indemnitors from any and all claims against the Fund Indemnitors for contribution, subrogation or any other recovery of any kind in respect thereof. The
Company further agrees that no advancement or payment by the Fund Indemnitors on behalf of any such Fund Director with respect to any claim for which such Fund Director has sought indemnification from the Company shall affect the foregoing and the
Fund Indemnitors shall have a right of contribution and/or be subrogated to the extent of such advancement or payment to all of the rights of recovery of such Fund Director against the Company. 

3.13 Termination of Covenants. Except as provided herein, the covenants set forth in this Section 3 shall
terminate immediately prior to the earlier to occur of: (a) an IPO or (b) an Acquisition. Notwithstanding the forgoing sentence, the covenants set forth in Sections 3.1 and 3.2 hereof will terminate immediately prior to the
earliest to occur of: (x) an IPO, (y) the time that the Company becomes subject to the reporting provisions of the Exchange Act, or (z) an Acquisition. 

  
 18 

 4. Restrictions on Transferability of Securities; Compliance with Securities Act.

 4.1 Restrictions on Transferability. The Restricted Securities shall not be sold, pledged, or otherwise transferred, and the
Company shall not recognize and shall issue stop-transfer instructions to its transfer agent with respect to any such sale, pledge, or transfer, except upon the conditions specified in this Agreement, which conditions are intended to ensure
compliance with the provisions of the Securities Act. A transferring Holder will cause any proposed purchaser, pledgee, or transferee of the Preferred Stock and the Registrable Securities held by such Holder to agree to take and hold such securities
subject to the provisions and upon the conditions specified in this Agreement. 
 4.2 Notice of Proposed Transfers. The Holder of
each certificate representing Restricted Securities by acceptance thereof agrees to comply in all respects with the provisions of this Section 4.2. 

(a) Before any proposed sale, pledge, or transfer of any Restricted Securities, unless there is in effect a registration statement under the
Securities Act covering the proposed transaction, the holder thereof shall give notice to the Company of such holder’s intention to effect such sale, pledge, or transfer. Each such notice shall describe the manner and circumstances of the
proposed sale, pledge, or transfer in sufficient detail and, if reasonably requested by the Company, shall be accompanied at such holder’s expense by either (i) a written opinion of legal counsel who shall, and whose legal opinion shall,
be reasonably satisfactory to the Company, addressed to the Company, to the effect that the proposed transaction may be effected without registration under the Securities Act; (ii) a “no action” letter from the SEC to the effect that
the proposed sale, pledge, or transfer of such Restricted Securities without registration will not result in a recommendation by the staff of the SEC that action be taken with respect thereto; or (iii) any other evidence reasonably satisfactory
to counsel to the Company to the effect that the proposed sale, pledge, or transfer of the Restricted Securities may be effected without registration under the Securities Act, whereupon the Holder of such Restricted Securities shall be entitled to
sell, pledge, or transfer such Restricted Securities in accordance with the terms of the notice given by the Holder to the Company. The Company will not require such a legal opinion or “no action” letter in any transaction in compliance
with SEC Rule 144; provided that each transferee agrees in writing to be subject to the terms of this Section 4.2. Each certificate or instrument evidencing the Restricted Securities transferred as above provided
shall bear, except if such transfer is made pursuant to Rule 144, the appropriate restrictive legend set forth in Section 3.6 of that certain Series A Preferred Stock Purchase Agreement, dated as of March 1, 2016, or Section 3.6 of
the Purchase Agreement, as applicable, except that such certificate shall not bear such restrictive legend if, in the opinion of counsel for such Holder and the Company, such legend is not required in order to establish compliance with any
provisions of the Securities Act. 
 (b) Notwithstanding the provisions of subsection (a) above, no such restriction shall apply to a
transfer by a holder that is (A) a partnership transferring to its partners or former partners in accordance with partnership interests, (B) a corporation transferring to a wholly-owned subsidiary, Affiliate or a parent corporation that
owns all of the capital stock of the holder, (C) a limited liability company transferring to its members or former members in accordance with their interest in the limited liability company, (D) an entity transferring to an Affiliate or
(E) an individual transferring to the holder’s family member or trust for the benefit of an individual holder; provided that in each case the transferee will agree in writing to be subject to the terms of this Agreement to the same
extent as if he were an original holder hereunder. 

  
 19 

 5. Miscellaneous. 

5.1 Successors and Assigns. Except as otherwise provided herein, the terms and conditions of this Agreement shall inure to the benefit
of and be binding upon the respective successors and assigns of the parties (including transferees of any shares of Registrable Securities). Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties
hereto or their respective successors and assigns any rights, remedies, obligations, or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement. 

5.2 Governing Law. This Agreement shall be governed by and construed under the laws of the State of California as applied to agreements
among California residents entered into and to be performed entirely within California. 
 5.3 Venue. Any suit or proceeding relating
to, arising out of or arising under this Agreement shall be brought in the federal or state courts located in San Mateo County, California, United States, which courts shall have the sole and exclusive in personam, subject matter and other
jurisdiction in connection with such suit or proceedings and venue shall be appropriate for all purposes in such courts. 
 5.4
Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. 

5.5 Titles and Subtitles. The titles and subtitles used in this Agreement are used for convenience only and are not to be considered in
construing or interpreting this Agreement. 
 5.6 Notices. All notices and other communications given or made pursuant to this
Agreement shall be in writing and shall be deemed effectively given upon the earliest of (a) personal delivery to the party to be notified, (b) when sent, if sent by electronic mail during normal business hours of the recipient, and if not
sent during normal business hours, then on the recipient’s next business day, provided that in either case it is followed promptly by a confirming copy of the notice given via another authorized means for that recipient, (c) five (5)
business days after having been sent to a U.S. address by registered or certified mail, return receipt requested, postage prepaid, (d) in the case of delivery to a U.S. address, one (1) business day after deposit with a nationally
recognized overnight courier, freight prepaid, specifying next business day delivery, with written verification of receipt, or (e) in the case of delivery to a non-U.S. address, three (3) business
days after deposit with an internationally recognized courier, freight prepaid, specifying next available business day delivery, with written verification of receipt; provided, however, that notice and other communications given or made to Roche
Finance Ltd shall only be provided using the methods set forth in clauses (a), (b) and (e) above. All communications to the Investors shall be sent to their respective addresses set forth on the signature page or Schedule A, or to such e-mail address or address as subsequently modified by written notice given in accordance with this Section 5.6. All communications to the Company shall be sent to: 

Ideaya Biosciences, Inc. 
 7000
Shoreline Court, Suite 350 
 South San Francisco, CA 94080 

Attn: Chief Executive Officer 

  
 20 

 with a copy (which shall not constitute notice) to: 

Latham & Watkins LLP 

140 Scott Drive 
 Menlo Park,
California 94025 
 Attn: Mark Roeder, Esq. 

Email: mark.roeder@lw.com 

Facsimile: (650) 463-2600 

5.7 Amendments and Waivers; Termination. This Agreement may be terminated, any term of this Agreement (other than Sections 3.1,
3.2, 3.3 and 3.9) may be amended, and the observance of any term of this Agreement may be waived (either generally or in a particular instance and either retroactively or prospectively), only with the written consent of the
Company and the Holders of at least 65% of the Registrable Securities then-outstanding; provided, however, that no consent or approval of any Holder shall be required to add persons as parties to this Agreement as Investors pursuant to
Section 5.10 or to revise Schedule A to include such parties; and provided further, however, that neither this Agreement nor any term hereof may be amended, waived, or terminated in a manner that materially,
adversely and disproportionately affects any Investor in a manner different than all other Investors (disregarding for such purpose differences in the number of shares held by Investors) without the written consent of such Investor. The provisions
of Sections 3.1, 3.2, 3.3 and 3.9 may be amended or waived (either generally or in a particular instance and either retroactively or prospectively) only with the written consent of the Company and the Major Investors
holding 65% of the Registrable Securities that are held by all of the Major Investors. The provisions of Section 3.10 relating to the Company’s (or its affiliates’) use of Celgene’s, Roche’s or
Novartis’ (or their respective affiliates’) names may be amended or waived only with the written consent of Celgene, Roche or Novartis, as the case may be, and for the avoidance of doubt, this sentence of this Section 5.7 shall not be
amended or waived with respect to Celgene, Roche or Novartis without such Investor’s written consent. To the extent that an amendment to Section 3.9 would impact an Investor with Observer Rights, such amendment shall
require the written consent of the impacted Investor with Observer Rights, as well as the written consent of the Company and the Holders of at least 65% of the Registrable Securities then-outstanding. Notwithstanding the foregoing, any right of any
party hereunder may be waived by the waiving party on such party’s own behalf, without the consent of any other party. Any amendment, waiver or termination effected in accordance with this Section 5.7 shall be binding
upon each Investor and the Company. 
 5.8 Severability. If any provision of this Agreement is held to be invalid, illegal or
unenforceable in any respect, such provision will be enforced to the maximum extent possible and such invalidity, illegality or unenforceability will not affect any other provision of this Agreement. In such event, the parties shall negotiate, in
good faith, a legal, valid and enforceable substitute provision which most nearly effects the intent of the parties in entering into this Agreement. 

5.9 Right to Invest. The Company on behalf of itself and its subsidiaries (a) acknowledges that certain of the Holders (the
“Investor Parties”) are in the business of making investments in, and have or may have investments in, other businesses similar to and that may compete with the businesses of the Company and its subsidiaries (“Competing
Businesses”) and (b) agrees that the Investor Parties shall have the unfettered right to make investments in or have relationships with other Competing Businesses independent of their investments in the Company. 

  
 21 

 5.10 Additional Parties. Persons who become “Purchasers” after the
effective date of this Agreement pursuant to and in accordance with the Purchase Agreement (each, an “Additional Party”), upon execution and delivery of counterpart signature pages to this Agreement, shall become parties hereto,
each such Additional Party thereby agreeing to be bound by and subject to the terms of this Agreement as an Investor hereunder. Each such Additional Party shall thereafter shall be deemed an Investor for all purposes under this Agreement. 

5.11 Delays or Omissions. No delay or omission to exercise any right, power or remedy accruing to either party to this Agreement, upon
any breach or default of the other party to this Agreement, shall impair any such right, power or remedy of such non-breaching or non-defaulting party nor shall it be
construed to be a waiver of any such breach or default, or an acquiescence therein, or of or in any similar breach or default thereafter occurring; nor shall any waiver of any single breach or default be deemed a waiver of any other breach or
default theretofore or thereafter occurring. Any waiver, permit, consent or approval of any kind or character on the part of any party of any breach or default under this Agreement, or any waiver on the part of any party of any provisions or
conditions of this Agreement, must be in writing and shall be effective only to the extent specifically set forth in such writing. All remedies, either under this Agreement or by law or otherwise afforded to any party, shall be cumulative and not
alternative. 
 5.12 Aggregation of Stock. All shares of Registrable Securities of the Company held or acquired by a stockholder and
its affiliated entities shall be aggregated together for the purpose of determining the availability of any rights under this Agreement. 

5.13 Electronic and Facsimile Signatures. Any signature page delivered electronically or by facsimile (including without limitation
transmission by .pdf) shall be binding to the same extent as an original signature page, with regard to any agreement subject to the terms hereof or any amendment thereto. Any party who delivers such a signature page agrees to later deliver an
original counterpart to the other party if so requested. 
 5.14 Entire Agreement. This Agreement (including all schedules and
exhibits attached hereto, if any) constitutes the full and entire understanding and agreement among the parties with respect to the subject matter hereof and hereby supersedes all other agreements of the parties to the extent such agreements relate
to the subject matter hereof. Upon the effectiveness of this Agreement, the Prior Agreement shall be deemed amended and restated and superseded in its entirety by this Agreement, and shall be of no further force or effect. 

5.15 Advice of Counsel. EACH PARTY TO THIS AGREEMENT ACKNOWLEDGES THAT, IN EXECUTING THIS AGREEMENT, SUCH PARTY HAS HAD THE OPPORTUNITY
TO SEEK THE ADVICE OF INDEPENDENT LEGAL COUNSEL, AND HAS READ AND UNDERSTOOD ALL OF THE TERMS AND PROVISIONS OF THIS AGREEMENT. THIS AGREEMENT SHALL NOT BE CONSTRUED AGAINST ANY PARTY BY REASON OF THE DRAFTING OR PREPARATION HEREOF. 

(Signature pages follow) 

  
 22

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00295-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00295-of-00352.parquet"}]]